1
|
Lee CC, Hwang JI, Chang KH, Lin YC, Chao CC, Cheng TF, Chen YC, Hsueh KC. Comparison of contrast-enhanced ultrasonography and MRI results obtained by expert and novice radiologists indicating short-term response after transarterial chemoembolisation for hepatocellular carcinoma. Clin Radiol 2024; 79:e73-e79. [PMID: 37914602 DOI: 10.1016/j.crad.2023.09.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Revised: 08/21/2023] [Accepted: 09/21/2023] [Indexed: 11/03/2023]
Abstract
AIM To evaluate inter-reader agreement between novice and expert radiologists in assessing contrast-enhanced ultrasonography (CEUS) and magnetic resonance imaging (MRI) images for detecting viable tumours with different sizes after conventional transarterial chemoembolisation (cTACE). MATERIALS AND METHODS This prospective study included patients who had less than five hepatomas and who underwent cTACE. Hepatomas with one or two feeding arteries were selected as target lesions. CEUS and MRI were performed within 1 week after cTACE to evaluate viable tumours. RESULTS The expert group had higher kappa values in evaluating all tumour sizes via CEUS compared with MRI. The novice group had similar kappa values. In patients with tumours measuring ≤3 cm, the expert group had higher kappa values in reading CEUS compared with MRI images; however, in the novice group, the kappa value was lower in evaluating CEUS compared with MRI images. In patients with tumours measuring >3 cm, the expert and novice groups had good to excellent kappa values. The confidence level of the two groups in reading MRI images was high; however, the novice group had a lower confidence level. CONCLUSION CEUS is a convenient, cost-effective, and easy to apply imaging tool that can help interventionists perform early detection of viable hepatocellular carcinoma post-TACE. It has a higher inter-rater agreement in interpreting CEUS images compared with MRI images among expert radiologists even when they are extremely familiar with post-cTACE MRI images. In novice radiologists, there may be a learning curve to achieve good consistency in CEUS interpretation.
Collapse
Affiliation(s)
- C-C Lee
- Division of Interventional Radiology, Department of Medical Imaging, Tungs' Taichung Metroharbor Hospital, Taichung 43503, Taiwan
| | - J-I Hwang
- Division of Interventional Radiology, Department of Medical Imaging, Tungs' Taichung Metroharbor Hospital, Taichung 43503, Taiwan; Department of Radiology, National Defense Medical Center, Taipei 11490, Taiwan
| | - K-H Chang
- Department of Medical Research, Tungs' Taichung Metroharbor Hospital, Taichung Taiwan; Center for General Education, China Medical University, Taichung 404, Taiwan; General Education Center, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli 356, Taiwan; Department of Life Sciences and Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung 40227, Taiwan
| | - Y C Lin
- Division of Interventional Radiology, Department of Medical Imaging, Tungs' Taichung Metroharbor Hospital, Taichung 43503, Taiwan
| | - C C Chao
- Division of Interventional Radiology, Department of Medical Imaging, Tungs' Taichung Metroharbor Hospital, Taichung 43503, Taiwan
| | - T-F Cheng
- Division of Interventional Radiology, Department of Medical Imaging, Tungs' Taichung Metroharbor Hospital, Taichung 43503, Taiwan
| | - Y-C Chen
- Division of Interventional Radiology, Department of Medical Imaging, Tungs' Taichung Metroharbor Hospital, Taichung 43503, Taiwan; Department of Medical Research, Tungs' Taichung Metroharbor Hospital, Taichung Taiwan
| | - K-C Hsueh
- Division of Interventional Radiology, Department of Medical Imaging, Tungs' Taichung Metroharbor Hospital, Taichung 43503, Taiwan; Division of General Surgery, Department of Surgery, Tungs' Taichung Metroharbor Hospital, Taichung 43503, Taiwan; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, 40227, Taiwan.
| |
Collapse
|
2
|
Gorelik M, Chung SA, Ardalan K, Binstadt BA, Friedman K, Hayward K, Imundo LF, Lapidus SK, Kim S, Son MB, Sule S, Tremoulet AH, Van Mater H, Yildirim-Toruner C, Langford CA, Maz M, Abril A, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Merkel PA, Rhee RL, Seo P, Stone JH, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot M, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis Rheumatol 2022; 74:586-596. [PMID: 35257501 DOI: 10.1002/art.42041] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 10/18/2021] [Accepted: 12/02/2021] [Indexed: 12/17/2022]
Abstract
OBJECTIVE To provide evidence-based recommendations and expert guidance for the management of Kawasaki disease (KD), focusing on clinical scenarios more commonly addressed by rheumatologists. METHODS Sixteen clinical questions regarding diagnostic testing, treatment, and management of KD were developed in the Patient/Population, Intervention, Comparison, and Outcomes (PICO) question format. Systematic literature reviews were conducted for each PICO question. We used the Grading of Recommendations, Assessment, Development and Evaluation method to assess the quality of evidence and formulate recommendations. Each recommendation required consensus from at least 70% of the Voting Panel. RESULTS We present 1 good practice statement, 11 recommendations, and 1 ungraded position statement to guide the management of KD and clinical scenarios of suspected KD. These recommendations for KD are focused on situations in which input from rheumatologists may be requested by other managing specialists, such as in cases of treatment-refractory, severe, or complicated KD. The good practice statement affirms that all patients with KD should receive initial treatment with intravenous immunoglobulin (IVIG). In addition, we developed 7 strong and 4 conditional recommendations for the management of KD or suspected KD. Strong recommendations include prompt treatment of incomplete KD, treatment with aspirin, and obtaining an echocardiogram in the setting of unexplained macrophage activation syndrome or shock. Conditional recommendations include use of IVIG with other adjuvant agents for patients with KD and high-risk features of IVIG resistance and/or coronary artery aneurysms. These recommendations endorse minimizing risk to the patient by using established therapy promptly at disease onset and identifying situations in which adjunctive therapy may be warranted. CONCLUSION These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and use of echocardiography in patients with suspected or confirmed KD.
Collapse
Affiliation(s)
- Mark Gorelik
- Columbia University School of Medicine, New York, New York
| | | | - Kaveh Ardalan
- Duke University School of Medicine, Durham, North Carolina
| | | | - Kevin Friedman
- Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts
| | - Kristen Hayward
- Seattle Children's Hospital and University of Washington School of Medicine, Seattle, Washington
| | - Lisa F Imundo
- Columbia University School of Medicine, New York, New York
| | - Sivia K Lapidus
- Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, and Hackensack Meridian School of Medicine, Hackensack, New Jersey
| | - Susan Kim
- University of California, San Francisco
| | - Mary Beth Son
- Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts
| | | | | | | | | | | | - Mehrdad Maz
- University of Kansas Medical Center, Kansas City
| | | | | | | | | | | | - Peter C Grayson
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland
| | | | | | | | - Philip Seo
- Johns Hopkins Medical Institute, Baltimore, Maryland
| | | | - Robert P Sundel
- Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts
| | | | - Ann Warner
- Saint Luke's Health System, Kansas City, Missouri
| | | | | | | | | | | | | | | | | | | | - Amy S Turner
- American College of Rheumatology, Atlanta, Georgia
| | | |
Collapse
|
3
|
Gorelik M, Chung SA, Ardalan K, Binstadt BA, Friedman K, Hayward K, Imundo LF, Lapidus SK, Kim S, Son MB, Sule S, Tremoulet AH, Van Mater H, Yildirim-Toruner C, Langford CA, Maz M, Abril A, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Merkel PA, Rhee RL, Seo P, Stone JH, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot M, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis Care Res (Hoboken) 2022; 74:538-548. [PMID: 35257507 DOI: 10.1002/acr.24838] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Accepted: 12/02/2021] [Indexed: 12/12/2022]
Abstract
OBJECTIVE To provide evidence-based recommendations and expert guidance for the management of Kawasaki disease (KD), focusing on clinical scenarios more commonly addressed by rheumatologists. METHODS Sixteen clinical questions regarding diagnostic testing, treatment, and management of KD were developed in the Patient/Population, Intervention, Comparison, and Outcomes (PICO) question format. Systematic literature reviews were conducted for each PICO question. We used the Grading of Recommendations, Assessment, Development and Evaluation method to assess the quality of evidence and formulate recommendations. Each recommendation required consensus from at least 70% of the Voting Panel. RESULTS We present 1 good practice statement, 11 recommendations, and 1 ungraded position statement to guide the management of KD and clinical scenarios of suspected KD. These recommendations for KD are focused on situations in which input from rheumatologists may be requested by other managing specialists, such as in cases of treatment-refractory, severe, or complicated KD. The good practice statement affirms that all patients with KD should receive initial treatment with intravenous immunoglobulin (IVIG). In addition, we developed 7 strong and 4 conditional recommendations for the management of KD or suspected KD. Strong recommendations include prompt treatment of incomplete KD, treatment with aspirin, and obtaining an echocardiogram in the setting of unexplained macrophage activation syndrome or shock. Conditional recommendations include use of IVIG with other adjuvant agents for patients with KD and high-risk features of IVIG resistance and/or coronary artery aneurysms. These recommendations endorse minimizing risk to the patient by using established therapy promptly at disease onset and identifying situations in which adjunctive therapy may be warranted. CONCLUSION These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and use of echocardiography in patients with suspected or confirmed KD.
Collapse
Affiliation(s)
- Mark Gorelik
- Columbia University School of Medicine, New York, New York
| | | | - Kaveh Ardalan
- Duke University School of Medicine, Durham, North Carolina
| | | | - Kevin Friedman
- Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts
| | - Kristen Hayward
- Seattle Children's Hospital and University of Washington School of Medicine, Seattle, Washington
| | - Lisa F Imundo
- Columbia University School of Medicine, New York, New York
| | - Sivia K Lapidus
- Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, and Hackensack Meridian School of Medicine, Hackensack, New Jersey
| | - Susan Kim
- University of California, San Francisco
| | - Mary Beth Son
- Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts
| | | | - Adriana H Tremoulet
- Rady Children's Hospital and University of California, San Diego, San Diego, California
| | | | | | | | - Mehrdad Maz
- University of Kansas Medical Center, Kansas City
| | | | | | | | | | | | - Peter C Grayson
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland
| | | | | | | | - Philip Seo
- Johns Hopkins Medical Institute, Baltimore, Maryland
| | | | - Robert P Sundel
- Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts
| | | | - Ann Warner
- Saint Luke's Health System, Kansas City, Missouri
| | | | | | | | | | | | | | | | | | | | - Amy S Turner
- American College of Rheumatology, Atlanta, Georgia
| | | |
Collapse
|
4
|
James KE, Kalot MA, Husainat NM, Dua AB, Byram K, Springer JM, Lin YC, Turgunbaev M, Villa-Forte A, Gorelik M, Abril A, Langford C, Maz M, Chung SA, Mustafa RA. Kawasaki Disease: A Systematic Review and Meta-Analysis of Benefits and Harms of Common Treatments. ACR Open Rheumatol 2021; 3:671-683. [PMID: 34313406 PMCID: PMC8516108 DOI: 10.1002/acr2.11308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2021] [Accepted: 06/21/2021] [Indexed: 11/06/2022] Open
Abstract
Objective Kawasaki disease (KD) is a self‐limited vasculitis affecting medium‐sized vessels with a predilection for the coronary arteries. Although treatment reduces the likelihood of developing of coronary artery aneurysms, 5% of patients still develop aneurysms despite treatment, making KD the leading cause of acquired heart disease in children in the United States. Consequently, there is a great deal of interest in optimizing treatment regimens, particularly for higher‐risk patients, to decrease morbidity. The aim of this systematic review is to support the development of the American College of Rheumatology/Vasculitis Foundation for the diagnosis and management of KD, focusing on the more complex scenarios in which rheumatologists may become involved, such as high‐risk and refractory disease. Methods Eighty‐nine articles were considered for full review in this systematic literature review to address 16 Population, Intervention, Comparison, and Outcome questions related to KD. Data were abstracted in hierarchical fashion. Randomized control trials (RCTs) were considered first; if none were identified or if they contained insufficient information, comparative observational studies were then viewed, followed by single‐arm observational studies/single arms from comparative studies. Only observational studies with more than 10 subjects with vasculitis were included. Results Eight RCTs and 28 observational studies that addressed the questions were identified. Two questions were addressed by RCTs, seven questions had at least some comparative observational studies, three questions were only addressed by single‐arm data, and four questions had no relevant studies. Conclusion This systematic review evaluates the benefits and harms of treatments for KD beyond first‐line therapy.
Collapse
Affiliation(s)
| | | | | | - Anisha B Dua
- Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Kevin Byram
- Vanderbilt University Medical Center, Nashville, Tennessee
| | | | | | - Marat Turgunbaev
- Clinical Practice Guidelines, American College of Rheumatology, Atlanta, Georgia
| | | | | | - Andy Abril
- Columbia University Irving Medical Center, New York, New York
| | | | - Mehrdad Maz
- University of Kansas Medical Center, Kansas City, KS
| | | | | |
Collapse
|
5
|
Chung SA, Gorelik M, Langford CA, Maz M, Abril A, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot M, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis Rheumatol 2021; 73:1384-1393. [PMID: 34235883 DOI: 10.1002/art.41776] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Accepted: 04/13/2021] [Indexed: 12/21/2022]
Abstract
OBJECTIVE To provide evidence-based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN). METHODS Twenty-one clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for systemic, non-hepatitis B-related PAN. Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. RESULTS We present 16 recommendations and 1 ungraded position statement for PAN. Most recommendations were graded as conditional due to the paucity of evidence. These recommendations support early treatment of severe PAN with cyclophosphamide and glucocorticoids, limiting toxicity through minimizing long-term exposure to both treatments, and the use of imaging and tissue biopsy for disease diagnosis. These recommendations endorse minimizing risk to the patient by using established therapy at disease onset and identify new areas where adjunctive therapy may be warranted. CONCLUSION These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and imaging for patients with PAN.
Collapse
Affiliation(s)
| | | | | | - Mehrdad Maz
- University of Kansas Medical Center, Kansas City
| | | | | | | | | | | | - Peter C Grayson
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland
| | | | | | - Susan Kim
- University of California, San Francisco
| | | | | | - Philip Seo
- Johns Hopkins University, Baltimore, Maryland
| | | | | | | | | | - Ann Warner
- Saint Luke's Health System, Kansas City, Missouri
| | | | | | | | | | | | | | | | | | | | - Amy S Turner
- American College of Rheumatology, Atlanta, Georgia
| | - Reem A Mustafa
- University of Kansas Medical Center, Kansas City, and McMaster University, Hamilton, Ontario, Canada
| |
Collapse
|
6
|
Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken) 2021; 73:1088-1105. [PMID: 34235880 DOI: 10.1002/acr.24634] [Citation(s) in RCA: 73] [Impact Index Per Article: 24.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Accepted: 04/13/2021] [Indexed: 12/18/2022]
Abstract
OBJECTIVE To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). METHODS Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. RESULTS We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low-quality evidence supporting the recommendations. CONCLUSION This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.
Collapse
Affiliation(s)
| | | | - Mehrdad Maz
- University of Kansas Medical Center, Kansas City
| | | | | | | | | | | | | | - Peter C Grayson
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland
| | | | | | - Susan Kim
- University of California, San Francisco
| | | | | | - Philip Seo
- Johns Hopkins University, Baltimore, Maryland
| | | | | | | | | | - Ann Warner
- Saint Luke's Health System, Kansas City, Missouri
| | | | | | | | | | | | | | | | | | | | - Amy S Turner
- American College of Rheumatology, Atlanta, Georgia
| | - Reem A Mustafa
- University of Kansas Medical Center, Kansas City, and McMaster University, Hamilton, Ontario, Canada
| |
Collapse
|
7
|
Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 2021; 73:1366-1383. [PMID: 34235894 DOI: 10.1002/art.41773] [Citation(s) in RCA: 194] [Impact Index Per Article: 64.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Accepted: 04/13/2021] [Indexed: 12/11/2022]
Abstract
OBJECTIVE To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). METHODS Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. RESULTS We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low-quality evidence supporting the recommendations. CONCLUSION This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.
Collapse
Affiliation(s)
| | | | - Mehrdad Maz
- University of Kansas Medical Center, Kansas City
| | | | | | | | | | | | | | - Peter C Grayson
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland
| | | | | | - Susan Kim
- University of California, San Francisco
| | | | | | - Philip Seo
- Johns Hopkins University, Baltimore, Maryland
| | | | | | | | | | - Ann Warner
- Saint Luke's Health System, Kansas City, Missouri
| | | | | | | | | | | | | | | | | | | | - Amy S Turner
- American College of Rheumatology, Atlanta, Georgia
| | - Reem A Mustafa
- University of Kansas Medical Center, Kansas City, and McMaster University, Hamilton, Ontario, Canada
| |
Collapse
|
8
|
Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol 2021; 73:1349-1365. [PMID: 34235884 DOI: 10.1002/art.41774] [Citation(s) in RCA: 171] [Impact Index Per Article: 57.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Revised: 01/24/2021] [Accepted: 04/13/2021] [Indexed: 12/14/2022]
Abstract
OBJECTIVE To provide evidence-based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. METHODS Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. Recommendations were developed by the Voting Panel, comprising adult and pediatric rheumatologists and patients. Each recommendation required ≥70% consensus among the Voting Panel. RESULTS We present 22 recommendations and 2 ungraded position statements for GCA, and 20 recommendations and 1 ungraded position statement for TAK. These recommendations and statements address clinical questions relating to the use of diagnostic testing, including imaging, treatments, and surgical interventions in GCA and TAK. Recommendations for GCA include support for the use of glucocorticoid-sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of nonglucocorticoid immunosuppressive agents with glucocorticoids as initial therapy. There were only 2 strong recommendations; the remaining recommendations were conditional due to the low quality of evidence available for most PICO questions. CONCLUSION These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.
Collapse
Affiliation(s)
- Mehrdad Maz
- University of Kansas Medical Center, Kansas City
| | | | | | | | | | | | | | | | | | - Peter C Grayson
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland
| | | | | | - Susan Kim
- University of California, San Francisco
| | | | | | - Philip Seo
- Johns Hopkins University, Baltimore, Maryland
| | | | | | | | | | - Ann Warner
- Saint Luke's Health System, Kansas City, Missouri
| | | | | | | | | | | | | | | | | | | | - Amy S Turner
- American College of Rheumatology, Atlanta, Georgia
| | - Reem A Mustafa
- University of Kansas Medical Center, Kansas City, and McMaster University, Hamilton, Ontario, Canada
| |
Collapse
|
9
|
Chung SA, Gorelik M, Langford CA, Maz M, Abril A, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot M, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis Care Res (Hoboken) 2021; 73:1061-1070. [PMID: 34235889 DOI: 10.1002/acr.24633] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Accepted: 04/13/2021] [Indexed: 01/18/2023]
Abstract
OBJECTIVE To provide evidence-based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN). METHODS Twenty-one clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for systemic, non-hepatitis B-related PAN. Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. RESULTS We present 16 recommendations and 1 ungraded position statement for PAN. Most recommendations were graded as conditional due to the paucity of evidence. These recommendations support early treatment of severe PAN with cyclophosphamide and glucocorticoids, limiting toxicity through minimizing long-term exposure to both treatments, and the use of imaging and tissue biopsy for disease diagnosis. These recommendations endorse minimizing risk to the patient by using established therapy at disease onset and identify new areas where adjunctive therapy may be warranted. CONCLUSION These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and imaging for patients with PAN.
Collapse
Affiliation(s)
| | | | | | - Mehrdad Maz
- University of Kansas Medical Center, Kansas City
| | | | | | | | | | | | - Peter C Grayson
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland
| | | | | | - Susan Kim
- University of California, San Francisco
| | | | | | - Philip Seo
- Johns Hopkins University, Baltimore, Maryland
| | | | | | | | | | - Ann Warner
- Saint Luke's Health System, Kansas City, Missouri
| | | | | | | | | | | | | | | | | | | | - Amy S Turner
- American College of Rheumatology, Atlanta, Georgia
| | - Reem A Mustafa
- University of Kansas Medical Center, Kansas City, and McMaster University, Hamilton, Ontario, Canada
| |
Collapse
|
10
|
Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Care Res (Hoboken) 2021; 73:1071-1087. [PMID: 34235871 DOI: 10.1002/acr.24632] [Citation(s) in RCA: 52] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Revised: 01/24/2021] [Accepted: 04/13/2021] [Indexed: 12/11/2022]
Abstract
OBJECTIVE To provide evidence-based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. METHODS Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. Recommendations were developed by the Voting Panel, comprising adult and pediatric rheumatologists and patients. Each recommendation required ≥70% consensus among the Voting Panel. RESULTS We present 22 recommendations and 2 ungraded position statements for GCA, and 20 recommendations and 1 ungraded position statement for TAK. These recommendations and statements address clinical questions relating to the use of diagnostic testing, including imaging, treatments, and surgical interventions in GCA and TAK. Recommendations for GCA include support for the use of glucocorticoid-sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of nonglucocorticoid immunosuppressive agents with glucocorticoids as initial therapy. There were only 2 strong recommendations; the remaining recommendations were conditional due to the low quality of evidence available for most PICO questions. CONCLUSION These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.
Collapse
Affiliation(s)
- Mehrdad Maz
- University of Kansas Medical Center, Kansas City
| | | | | | | | | | | | | | | | | | - Peter C Grayson
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland
| | | | | | - Susan Kim
- University of California, San Francisco
| | | | | | - Philip Seo
- Johns Hopkins University, Baltimore, Maryland
| | | | | | | | | | - Ann Warner
- Saint Luke's Health System, Kansas City, Missouri
| | | | | | | | | | | | | | | | | | | | - Amy S Turner
- American College of Rheumatology, Atlanta, Georgia
| | - Reem A Mustafa
- University of Kansas Medical Center, Kansas City, and McMaster University, Hamilton, Ontario, Canada
| |
Collapse
|
11
|
Dua AB, Husainat NM, Kalot MA, Byram K, Springer JM, James KE, Chang Lin Y, Turgunbaev M, Villa-Forte A, Abril A, Langford C, Maz M, Chung SA, Mustafa RA. Giant Cell Arteritis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatol 2021; 3:429-441. [PMID: 33811481 PMCID: PMC8280815 DOI: 10.1002/acr2.11226] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Accepted: 11/25/2020] [Indexed: 01/31/2023] Open
Abstract
This systematic review compares treatment options for patients with giant cell arteritis (GCA) and evaluates the test accuracy of studies used in diagnosing and monitoring GCA. These studies were used to inform evidence-based recommendations for the American College of Rheumatology (ACR)/Vasculitis Foundation (VF) vasculitis management guidelines. A systematic review and search of articles in English in Ovid Medline, PubMed, Embase, and the Cochrane Library was conducted. Articles were screened for suitability, and studies presenting the highest level of evidence were given preference. Three hundred ninety-nine full-text articles addressing GCA questions were reviewed to inform 27 Population, Intervention, Comparison, and Outcome questions. No benefit was found with intravenous glucocorticoids (GCs) compared with high-dose oral GCs in patients with cranial ischemic symptoms (27.4% vs 12.3%; odds ratio [OR] 2.39 [95% confidence interval (CI) 0.75-7.62], [very low certainty of evidence]). Weekly tocilizumab with a 26-week GC taper was superior to a 52-week GC taper in patients achieving remission (risk ratio 4.00 [95% CI 1.97-8.12], [low certainty of evidence]). Non-GC immunosuppressive therapies with GCs compared with GCs alone showed no statistically significant in relapse at 1 year (OR 0.87 [95% CI 0.73-1.04], [moderate certainty of evidence]) or serious adverse events (OR 0.81 [95% CI 0.54-1.20]; [moderate certainty of evidence]). Temporal artery biopsy has a sensitivity of 61% (95% CI 38%-79%) and a specificity of 98% (95% CI 95%-99%) in patients with a clinical diagnosis of suspected GCA. This comprehensive systematic review synthesizes and evaluates the benefits and harms of different treatment options and the accuracy of commonly used tests for the diagnosis and monitoring of GCA.
Collapse
Affiliation(s)
- Anisha B Dua
- Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | | | | | - Kevin Byram
- Vanderbilt University Medical Center, Nashville, Tennessee
| | | | | | | | | | | | | | | | - Mehrdad Maz
- University of Kansas Medical Center, Kansas City
| | | | | |
Collapse
|
12
|
Springer JM, Kalot MA, Husainat NM, Byram KW, Dua AB, James KE, Chang Lin Y, Turgunbaev M, Villa-Forte A, Abril A, Langford C, Maz M, Chung SA, Mustafa RA. Granulomatosis With Polyangiitis and Microscopic Polyangiitis: A Systematic Review and Meta-Analysis of Benefits and Harms of Common Treatments. ACR Open Rheumatol 2021; 3:196-205. [PMID: 33590973 PMCID: PMC7966881 DOI: 10.1002/acr2.11230] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2020] [Accepted: 12/31/2020] [Indexed: 11/11/2022] Open
Abstract
OBJECTIVE The aim of this systemic review is to compare different treatments for patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) to inform evidence-based recommendations for the American College of Rheumatology (ACR)/Vasculitis Foundation (VF) Vasculitis Management Guidelines. METHODS A systemic review was conducted by searching articles in English using OVID Medline, PubMed, Embase, and the Cochrane Library. Articles were screened for suitability in addressing PICO questions, with studies presenting the highest level of evidence given preference. RESULTS A total of 729 full-text articles addressing GPA and MPA PICO questions were reviewed. For remission induction, rituximab was shown to be noninferior to cyclophosphamide (CYC) (odds ratio [OR]: 1.55, moderate certainty of evidence). The addition of plasma exchange to induction therapy in severe disease did not improve the composite end point of death or end stage renal disease (hazard ratio [HR]: 0.86 [95% confidence interval CI: 0.65, 1.13], moderate certainty of evidence). In nonsevere disease, methotrexate was noninferior to CYC for induction of remission (remission at 6 months of 90% vs. 94%). For maintenance of remission, methotrexate and azathioprine showed no difference in the risk of relapse over a mean follow-up of 29 months (HR: 0.92, [95% CI: 0.52, 1.65]low certainty of evidence). As maintenance therapy, rituximab was superior to a tapering azathioprine strategy in major relapse-free survival at 28 months (HR: 6.61, [95% CI: 1.56, 27.96], moderate certainty of evidence). In two randomized trials, longer-term azathioprine maintenance therapy (>24 months) is associated with fewer relapses without an increase in adverse events. CONCLUSION This comprehensive systematic review synthesizes and evaluates the benefits and toxicities of different treatment options for GPA and MPA.
Collapse
Affiliation(s)
| | | | | | - Kevin W Byram
- Vanderbilt University Medical Center, Nashville, Tennessee
| | - Anisha B Dua
- Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | | | | | | | | | | | | | - Mehrdad Maz
- University of Kansas Medical Center, Kansas City, Kansas
| | | | - Reem A Mustafa
- University of Kansas Medical Center, Kansas City, Kansas
| |
Collapse
|
13
|
Lin YC, Kalot MA, Husainat NM, Byram K, Dua AB, James KE, Springer JM, Turgunbaev M, Villa-Forte A, Abril A, Langford C, Maz M, Chung SA, Mustafa RA. Polyarteritis Nodosa: A Systematic Review of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatol 2021; 3:91-100. [PMID: 33512781 PMCID: PMC7882539 DOI: 10.1002/acr2.11189] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Accepted: 09/28/2020] [Indexed: 11/08/2022] Open
Abstract
OBJECTIVE The object of this study was to analyze the benefits and harms of different treatment options and to analyze test accuracy used in the evaluation of patients with primary systemic polyarteritis nodosa (PAN). METHODS A systematic search of published English-language literature was performed in Ovid Medline, PubMed, Embase, and the Cochrane Library from the inception of each database through August 2019. Articles were screened for suitability in addressing patient, intervention, comparison, and outcome questions, with studies presenting the highest level of evidence given preference. RESULTS Of 137 articles selected for data abstraction, we analyzed 21 observational studies and seven randomized controlled trials (RCTs). The results showed indirect evidence that a deep skin biopsy provides good diagnostic accuracy. A combined nerve and muscle biopsy should be obtained for patients with PAN with peripheral neuropathy. Cyclophosphamide with high-dose glucocorticoids (GCs) is effective as an induction treatment for newly diagnosed active and severe PAN. GC monotherapy is adequate in the majority of patients with nonsevere PAN, although it has a high relapse rate with GC taper. There was insufficient data in determining the optimal duration of non-GC and GC maintenance therapy. Tumor necrosis factor inhibitors are effective treatment for patients with deficiency of adenosine deaminase 2 (DADA2) with stroke and vasculitis manifestations. CONCLUSION This comprehensive systematic review synthesizes and evaluates the harms and benefits of different treatment options and the accuracy of commonly used tests for the diagnosis of systemic PAN. Data for diagnosis and management of PAN and DADA2 are mostly limited to observational studies. More high-quality RCTs are needed.
Collapse
Affiliation(s)
- Yih Chang Lin
- University of South Florida, Tampa, Florida, United States
| | - Mohamad A Kalot
- The State University of New York at Buffalo, New York, United States
| | | | - Kevin Byram
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
| | - Anisha B Dua
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
| | - Karen E James
- University of Utah Health, Salt Lake City, United States
| | - Jason M Springer
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
| | - Marat Turgunbaev
- American College of Rheumatology, Atlanta, Georgia, United States
| | | | - Andy Abril
- Mayo Clinic, Jacksonville, Florida, United States
| | | | - Mehrdad Maz
- University of Kansas Medical Center, Kansas City, United States
| | - Sharon A Chung
- University of California, San Francisco Medical Center, California, United States
| | - Reem A Mustafa
- University of Kansas Medical Center, Kansas City, United States.,Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada
| |
Collapse
|
14
|
Dua AB, Kalot MA, Husainat NM, Byram K, Springer JM, James KE, Chang Lin Y, Turgunbaev M, Villa-Forte A, Abril A, Langford C, Maz M, Chung SA, Mustafa RA. Takayasu Arteritis: a Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatol 2021; 3:80-90. [PMID: 33512784 PMCID: PMC7882531 DOI: 10.1002/acr2.11186] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Accepted: 09/16/2020] [Indexed: 12/13/2022] Open
Abstract
Objective Takayasu’s arteritis (TAK) is a granulomatous large‐vessel vasculitis primarily affecting the aorta and its proximal branches. TAK can be a difficult disease to diagnose and manage given the rarity of the disease as well as current limitations in biomarkers, imperfect imaging modalities, and few randomized controlled trials. Methods In developing the American College of Rheumatology/Vasculitis Foundation guideline for the management of TAK, we performed an extensive systematic literature review to guide our recommendations. We included RCTs first. When RCTs were not available, we included observational studies that reported on patient‐important outcomes for the intervention and comparison. When studies with comparative data were not available, we included case series that present patient‐important outcomes for either the intervention or the comparison. Results Three hundred forty‐seven articles were included for full review to answer 27 population, intervention, comparison, and outcome questions related to TAK. Ten studies were evaluated that addressed the use of glucocorticoids (GCs), non‐GC nonbiologic therapies, as well as biologics in treating TAK. A total of 33 studies, including 8 comparative studies, were included to determine the test accuracy of commonly available diagnostic tests for TAK. Conclusion This comprehensive systematic review synthesizes and evaluates the benefits and harms of different treatment options and the accuracy of commonly used tests for the management of TAK.
Collapse
Affiliation(s)
- Anisha B Dua
- Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | | | | | - Kevin Byram
- Vanderbilt University Medical Center, Nashville, Tennessee
| | | | | | | | | | | | | | | | - Mehrdad Maz
- University of Kansas Medical Center, Kansas City
| | | | | |
Collapse
|
15
|
Springer JM, Kalot MA, Husainat NM, Byram KW, Dua AB, James KE, Chang Lin Y, Turgunbaev M, Villa-Forte A, Abril A, Langford CA, Maz M, Chung SA, Mustafa RA. Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatol 2021; 3:101-110. [PMID: 33512787 PMCID: PMC7882521 DOI: 10.1002/acr2.11194] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Accepted: 10/07/2020] [Indexed: 12/18/2022] Open
Abstract
Objective Eosinophilic granulomatosis with polyangiitis (EGPA) is part of a group of vasculitides commonly referred to as antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV), in addition to granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and renal‐limited vasculitis. Patients with EGPA characteristically have asthma and marked peripheral eosinophilia with only approximately 30% to 35% of patients being myeloperoxidase (MPO)‐ANCA positive, distinguishing it from other forms of AAV (1,2). The aim of this systematic review is to support the development of the American College of Rheumatology/Vasculitis Foundation guideline for the management of EGPA. Methods A systematic review was conducted of the literature for seven forms of primary systemic vasculitis (GPA, MPA, EGPA, polyarteritis nodosa, Kawasaki disease, giant cell arteritis, and Takayasu arteritis). The search was done for articles in English using Ovid Medline, PubMed, Embase, and the Cochrane Library. Articles were screened for suitability in addressing population/patients, intervention, comparator, and outcomes (PICO) questions, with studies presenting the highest level of evidence given preference. Two independent reviewers conducted a title/abstract screen and full‐text review for each eligible study. Results The initial search, conducted in August 2019, included 13 800 articles, of which 2596 full‐text articles were reviewed. There were 190 articles (addressing 34 PICO questions) reporting on the diagnosis and management of EGPA. Conclusion This comprehensive systematic review synthesizes and evaluates the accuracy of commonly used tests for EGPA as well as benefits and toxicities of different treatment options.
Collapse
Affiliation(s)
| | | | | | | | - Anisha B Dua
- Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | | | | | | | | | | | | | - Mehrdad Maz
- University of Kansas Medical Center, Kansas City
| | | | | |
Collapse
|
16
|
Lin YC, Chou SH, Hsueh WJ. Tunable light absorption of graphene using topological interface states. Opt Lett 2020; 45:4369-4372. [PMID: 32796960 DOI: 10.1364/ol.397738] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 06/26/2020] [Indexed: 06/11/2023]
Abstract
A tunable light absorption of graphene using topological interface states (TISs) is presented. The monolayer graphene is embedded in the interface of asymmetric topological photonic crystals (ATPCs). A strong absorption phenomenon occurs by the excitation of TISs. It is found that the absorption spectra are intensively dependent on the chemical potential of graphene and the periodic number of the ATPCs. Furthermore, the absorption can be rapidly switched in a slight variation of chemical potential, which is modulated by the applied gate voltage on graphene. This study not only opens up a new approach for enhancing light-monolayer graphene interactions, but also provides for practical applications in high absorption optoelectronic devices. This strong absorption phenomenon is different from those in Fabry-Perot resonators, nano-cavities photonic crystal, and traditional topological photonic crystals (TPCs).
Collapse
|
17
|
Lin YC, Yan HT. Media Freedom is the Primary Culprit for Depressive Disorders: A Cross-National Analysis. Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz187.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
There has been much speculation about social environments causing an epidemic of depression. The objectives of this study are to examine how media freedom influences prevalence of depressive disorders. A direct effect of free media is great levels of information complexity causing poor mental health. Two indirect effects are that media freedom facilitates modernization, which is associated with competition-related stress, and government investment in social protection, which impedes the person’s ability to manage stress.
Methods
The study used a cross-sectional analysis on determinants of prevalence of depressive disorders in 2015 covering 98 democratic countries. Media freedom was measured as the degree to which a country allows the freedom of news and information of print media, television, and radio broadcasting (0-100: least to most free). Control variables were then added, including GDP per capita growth, population density, country latitude, and religious affiliations. Further, a mediation analysis was applied to test if there is a causal pathway that links the degrees of media freedom and the levels of economic development or/and social protection to prevalence of depression.
Results
We found that an increase in the score of media freedom by 10 resulted in a 0.20 percentage point increase in prevalence of depressive disorders (%) (0.20, CI = 0.10-0.30). Our theoretical expectations were still confirmed when this study examined the relationship for each year between 2011 and 2014 (e.g. in 2014, 0.19, CI = 0.09-0.29), used an alternative index of media freedom from a practitioners’ view (0.17, CI = 0.02-0.32), or measured each country’s level of internet and digital media freedom (0.30, CI = 0.10-0.49). Further, a mediation test showed that 39.88% and 21.38% of the total effect was mediated through the economic and social pathway respectively.
Conclusions
The findings suggest that great levels of media freedom matter in increasing prevalence of depression.
Key messages
Great levels of media freedom matter in increasing prevalence of depression. There are direct and two indirect effects of media freedom on prevalence of depression.
Collapse
Affiliation(s)
- Y C Lin
- Chinese Medicine Department, China Medical University Hospital, Taichung City, Taiwan
| | - H T Yan
- Department of Government, University of Essex, Colchester, UK
| |
Collapse
|
18
|
Chiang JY, Fu CM, Lin YC, Ku BW, Hsu SU, Wu CK, Lin LY, Lin JL, Chiang FT, Juang JM. P1880Entropy-based algorithm for atrial fibrillation detection using photoplethysomgraphic signal recorded by a smart watch. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Atrial fibrillation (AF) is the most common arrhythmia, and its paroxysmal and short duration nature makes its detection challenging. The most important limitation of current smartwatches is that patients need to touch to the sensor of the watch to record signals when patients feel discomfort. We developed a wearable smart watch and evaluated its accuracy to differentiate AF from sinus rhythm, which can continuously detecting heart rhythm without hand touching the device.
Methods and results
A wearable smart watch with PPG sensor and electrocardiogram (ECG) recording function was used for signal acquisition. A total 399 patients with a mean age of 67 years old were enrolled in the study, of whom 237 (81.5%) were male, and 101 have been diagnosed with AF. Pulse wave extracted from the green light spectrum of the signal and ECG were recorded for about 10 minutes for each patient. Pulse-to-pulse intervals (PPI) were automatically identified. All ECG signals were verified by two cardiologists. The correlation between R-to-R interval on ECG and PPI were excellent, with a correlation coefficient R >0.99 (p<0.05). An entropy-based algorithm which combined Shannon entropy of successive difference of PPI and sample entropy of PPI was used to discriminate between AF and sinus rhythm. This method had high sensitivity and specificity (96% and 98%, respectively), the area under receiver operating characteristic curve reached 0.98.
Conclusions
We developed an entropy-based algorithm for AF detection with PPG signal recorded by a wearable smart watch. This algorithm discriminates AF from sinus rhythm accurately. This advance in technology overcomes an important clinical obstacle and can increase the AF detection rate tremendously.
Collapse
Affiliation(s)
- J Y Chiang
- National Taiwan University Hospital, Internal medicine, Taipei, Taiwan
| | - C M Fu
- MediaTek Inc, Taipei, Taiwan
| | - Y C Lin
- MediaTek Inc, Taipei, Taiwan
| | - B W Ku
- MediaTek Inc, Taipei, Taiwan
| | - S U Hsu
- MediaTek Inc, Taipei, Taiwan
| | - C K Wu
- MediaTek Inc, Taipei, Taiwan
| | - L Y Lin
- National Taiwan University Hospital, Division of Cardiology, Department of Internal Medicine, Taipei, Taiwan
| | - J L Lin
- National Taiwan University Hospital, Division of Cardiology, Department of Internal Medicine, Taipei, Taiwan
| | - F T Chiang
- National Taiwan University Hospital, Division of Cardiology, Department of Internal Medicine, Taipei, Taiwan
| | - J M Juang
- National Taiwan University Hospital, Division of Cardiology, Department of Internal Medicine, Taipei, Taiwan
| |
Collapse
|
19
|
Li MY, Ye J, Huang ZY, Lin YC, Liu AH, Li LP, Chen J, Wang YP. [Clinical analysis of five cases of autism spectrum disorder complicated with epilepsy with chromosome copy number variation]. Zhonghua Yi Xue Za Zhi 2019; 99:2615-2618. [PMID: 31510723 DOI: 10.3760/cma.j.issn.0376-2491.2019.33.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To explore the clinical features and genetic causes of autism spectrum disorder (ASD) patients with epilepsy. Methods: The clinical data of five patients with ASD and epilepsy admitted to Xuanwu Hospital between September 2017 and September 2018 were collected, including medical history, intelligence level, developmental level, physical examination, neuroimaging and electroencephalogram. High-throughput whole-genome sequencing was applied to five patients and their parents. Results: Of five patients, four were male and one was female. All five patients had mild mental retardation, and one patient had significant growth retardation and craniofacial deformity. The average epilepsy onset age was 6.3 years old (7 months to 16 years). The main epileptic type was tonic-clonic seizure with abnormal EEG results. All patients have a favorable response to anti-epileptic drugs. Whole-exome sequencing (WES) revealed copy number variation in all 5 patients. Among them, 3 cases were reported to be pathogenic, and 2 cases were not reported (chromosome 16p13.3 duplication and chromosome 21q22.3 deletion). Conclusions: The results of current study support that autism spectrum disorders with seizures is often associated with copy number variations, such as Williams-Beuren region duplication syndrome, chromosome 15q11.2 duplication syndrome and chromosome 15q11.2 deletion syndrome. We reported two novel copy number variations (chromosome 16p13.3 duplication and chromosome 21q22.3 deletion) in two autism spectrum disorder patients with epileptic seizures.
Collapse
Affiliation(s)
- M Y Li
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
We report a 49-year-old woman who presented with a hypertensive crisis and acute heart failure and reduced left ventricular systolic function. An abdominal ultrasonography revealed a huge lobulated heterogeneous mass at the lower pole of the right kidney and a mass over the left suprarenal area, which were further delineated by magnetic resonance imaging. The patient underwent laparoscopic right radical nephrectomy and left adrenalectomy. Histopathological analysis confirmed the diagnoses of clear cell renal cell carcinoma of the right kidney with metastasis to the lung; and atypical pheochromocytoma of the left adrenal gland. Target therapy was initiated, which resulted in stabilization of the patient's tumors and the recovery of her heart function. To avoid a delayed diagnosis and catastrophic outcome, clinicians should consider such rare causes of acute decompensated heart failure.
Collapse
Affiliation(s)
- H H Chen
- School of Medicine, National Defense Medical Center, Taipei, Taiwan
| | - S T Wu
- Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
| | - Y C Lin
- Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
| | - C S Lin
- Division of Cardiology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
| |
Collapse
|
21
|
Leng XR, Ye J, Zhou QL, Qi XH, Dong YH, Zhang LP, Zhang YF, Wang YP, Li LP, Lin YC. [Clinical features and gene analysis of TBC1D24 gene mutation related early-onset focal myoclonic epilepsy]. Zhonghua Yi Xue Za Zhi 2018; 98:445-449. [PMID: 29429257 DOI: 10.3760/cma.j.issn.0376-2491.2018.06.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the clinical features and genetic characteristics of patients with TBC1D24 gene mutation related early-onset focal myoclonic epilepsy. Methods: Clinical data of 3 patients with TBC1D24 gene mutation related early-onset focal myoclonic epilepsy of Xuanwu Hospital from November 2016 to June 2017 was collected and analyzed.Candidate gene mutations were screened by second generation sequencing. Results: Among the 3 patients, 1 was male and 2 were females.Seizure onset age was 4 months, 3 years and 5 years after birth respectively. Two patients had family history of epilepsy.They all had prolonged episodes of focal myoclonus. Two patients had mental retardation.Scalp electroencephalograms (EEG) was recorded in all 3 cases and myoclonic seizures were captured.The ictal EEGs were normal in all cases. In one patient, the ictal EEG of generalized seizure showed alpha rhythm originating from left fronto-central region. Brain magnetic resonance imaging (MRI) was normal in 2 patients. Abnormal signal was found bilaterally in cerebellum in 1 patient. The gene screening showed that two patients carried compound heterozygous mutation of TBC1D24 gene and one carried homozygous mutation, all of which were de novo mutations.All the patients were treated with multiple antiepileptic drugs (AEDs) and seizures were uncontrolled in 2 patients. One patient was followed up for 10 months without recurrence. Conclusions: TBC1D24 gene related early-onset focal myoclonic epilepsy is clinically characterized by early onset, prolonged focal myoclonus which relieved with sleep, mental retardation and poor response to AEDs.The interictal and ictal EEG usually show normal. Genetic analysis can assist in diagnosis and genetic counseling.
Collapse
Affiliation(s)
- X R Leng
- Department of Pediatrics, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Lin YC, Chang YH. Poor appetite and long-term risk of falls among middle-aged and older adults: A longitudinal study. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky214.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- YC Lin
- Department of Chinese Medicine, China Medical University Hospital, Taichung City, Taiwan
| | - YH Chang
- Department of Public Health, China Medical University, Taichung City, Taiwan
| |
Collapse
|
23
|
Lin YC, Tsou CH, Hsueh WJ. Ultra-slow light in one-dimensional Cantor photonic crystals. Opt Lett 2018; 43:4120-4123. [PMID: 30160731 DOI: 10.1364/ol.43.004120] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Accepted: 07/26/2018] [Indexed: 06/08/2023]
Abstract
Ultra-slow light and complete transmission properties in one-dimensional Cantor photonic crystals are presented. In contrast to traditional dielectric photonic crystals, the proposed structure has large group delay, slower group velocity, and a high quality factor within the same layers and materials. This study shows that larger than 1 μs group delay and slower than 1 m/s group velocity are achieved in the fifth-order Cantor photonic crystal with 52.75 μm length. This ultra-slow-light structure is very promising for application in advanced slow-light devices. A high quality factor of 109 and multiband filters with complete transmission can also be obtained by using this approach.
Collapse
|
24
|
Petrov NV, Nalegaev SS, Belashov AV, Shevkunov IA, Putilin SE, Lin YC, Cheng CJ. Time-resolved inline digital holography for the study of noncollinear degenerate phase modulation. Opt Lett 2018; 43:3481-3484. [PMID: 30067690 DOI: 10.1364/ol.43.003481] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/13/2018] [Accepted: 06/08/2018] [Indexed: 06/08/2023]
Abstract
Recent works demonstrated that digital time-resolved holography is the prospective approach to study nonlinear light-matter interaction processes. In this Letter, we present a straightforward inline holographic approach for studying degenerate phase modulation induced by an inclined collimated pump beam in the isotropic sample. The method is based on a minimization of the difference between experimentally acquired data and simulated inline holograms obtained from a numerical model of pump-probe interaction in optical nonlinear media. A sophisticated experimental data processing algorithm is implemented to provide high sensitivity and a signal-to-noise ratio eligible for soft interaction with a collimated pump beam. The integral phase shift determined by our method can be used to estimate the nonlinear refractive index and the relaxation time for material with a low damage threshold. We validated our approach for the case of soda-lime and BK7 glasses.
Collapse
|
25
|
Chen W, Wang S, Zhang HX, Ruan D, Xia WG, Cui YY, Zheng CT, Lin YC. Optimization of dietary zinc for egg production and antioxidant capacity in Chinese egg-laying ducks fed a diet based on corn-wheat bran and soybean meal. Poult Sci 2018; 96:2336-2343. [PMID: 28339968 DOI: 10.3382/ps/pex032] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Accepted: 02/24/2017] [Indexed: 11/20/2022] Open
Abstract
The aim of this study was to evaluate the effect of zinc supplementation on productive performance and antioxidant status in laying ducks. Five-hundred-four laying ducks were divided into 7 treatments, each containing 6 replicates of 12 ducks. The ducks were caged individually and fed a corn-soybean meal and wheat bran basal diet (37 mg Zn/kg) or the basal diet supplemented with 15, 30, 45, 60, 75, or 90 mg Zn/kg (as zinc sulfate). During the early laying period of 10 d (daily egg production <80%), egg production, daily egg mass, and FCR increased quadratically with increasing dietary Zn levels (P < 0.05). The highest egg production and daily egg weight were obtained when 30 or 45 mg Zn/kg diet was supplemented, with lowest FCR. Similarly, the highest egg production and daily egg mass were observed in the group supplemented with 30 or 45 mg Zn/kg during the peak laying period of the subsequent 120 d (daily egg production >80%). Average egg weight and feed intake did not differ among the groups of graded Zn supplementation.The egg quality was not affected by dietary Zn, including the egg shape index, Haugh unit, yolk color score, egg composition, and shell thickness. The activities of plasma activities of total superoxide dismutase (T-SOD) and glutathione peroxidase (GSH-PX) increased in a quadratic manner (P < 0.001) with increasing supplemental Zn. Plasma concentration of Zn increased quadratically (P < 0.05) as dietary Zn increased. The hepatic activity of Cu/Zn-SOD and GSH-PX increased quadratically (P < 0.05) with increasing dietary Zn. Plasma Zn concentrations were positively correlated with activities of T-SOD (P < 0.05), and positively with plasma Cu. Plasma concentration of reduced glutathione was correlated with plasma Cu. In conclusion, supplementation of Zn at 30 or 45 mg/kg to a corn-wheat bran and soybean basal diet may improve the productive performance and enhance the antioxidant capacity.
Collapse
Affiliation(s)
- W Chen
- Institute of Animal Science, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China.,State Key Laboratory of Livestock and Poultry Breeding, Guangzhou 510640, China.,Key Laboratory of Animal Nutrition and Feed Science in South China, Ministry of Agriculture, Guangzhou 510640, China.,Guangdong Public Laboratory of Animal Breeding and Nutrition, Guangzhou 510640, China.,Guangdong Key Laboratory of Animal Breeding and Nutrition, Guangzhou 510640, China
| | - S Wang
- Institute of Animal Science, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China.,State Key Laboratory of Livestock and Poultry Breeding, Guangzhou 510640, China.,Key Laboratory of Animal Nutrition and Feed Science in South China, Ministry of Agriculture, Guangzhou 510640, China.,Guangdong Public Laboratory of Animal Breeding and Nutrition, Guangzhou 510640, China.,Guangdong Key Laboratory of Animal Breeding and Nutrition, Guangzhou 510640, China
| | - H X Zhang
- Institute of Animal Science, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China.,State Key Laboratory of Livestock and Poultry Breeding, Guangzhou 510640, China.,Key Laboratory of Animal Nutrition and Feed Science in South China, Ministry of Agriculture, Guangzhou 510640, China.,Guangdong Public Laboratory of Animal Breeding and Nutrition, Guangzhou 510640, China.,Guangdong Key Laboratory of Animal Breeding and Nutrition, Guangzhou 510640, China
| | - D Ruan
- Institute of Animal Science, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China.,State Key Laboratory of Livestock and Poultry Breeding, Guangzhou 510640, China.,Key Laboratory of Animal Nutrition and Feed Science in South China, Ministry of Agriculture, Guangzhou 510640, China.,Guangdong Public Laboratory of Animal Breeding and Nutrition, Guangzhou 510640, China.,Guangdong Key Laboratory of Animal Breeding and Nutrition, Guangzhou 510640, China
| | - W G Xia
- Institute of Animal Science, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China.,State Key Laboratory of Livestock and Poultry Breeding, Guangzhou 510640, China.,Key Laboratory of Animal Nutrition and Feed Science in South China, Ministry of Agriculture, Guangzhou 510640, China.,Guangdong Public Laboratory of Animal Breeding and Nutrition, Guangzhou 510640, China.,Guangdong Key Laboratory of Animal Breeding and Nutrition, Guangzhou 510640, China
| | - Y Y Cui
- Institute of Animal Science, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China.,State Key Laboratory of Livestock and Poultry Breeding, Guangzhou 510640, China.,Key Laboratory of Animal Nutrition and Feed Science in South China, Ministry of Agriculture, Guangzhou 510640, China.,Guangdong Public Laboratory of Animal Breeding and Nutrition, Guangzhou 510640, China.,Guangdong Key Laboratory of Animal Breeding and Nutrition, Guangzhou 510640, China
| | - C T Zheng
- Institute of Animal Science, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China.,State Key Laboratory of Livestock and Poultry Breeding, Guangzhou 510640, China.,Key Laboratory of Animal Nutrition and Feed Science in South China, Ministry of Agriculture, Guangzhou 510640, China.,Guangdong Public Laboratory of Animal Breeding and Nutrition, Guangzhou 510640, China.,Guangdong Key Laboratory of Animal Breeding and Nutrition, Guangzhou 510640, China
| | - Y C Lin
- Institute of Animal Science, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China.,State Key Laboratory of Livestock and Poultry Breeding, Guangzhou 510640, China.,Key Laboratory of Animal Nutrition and Feed Science in South China, Ministry of Agriculture, Guangzhou 510640, China.,Guangdong Public Laboratory of Animal Breeding and Nutrition, Guangzhou 510640, China.,Guangdong Key Laboratory of Animal Breeding and Nutrition, Guangzhou 510640, China
| |
Collapse
|
26
|
Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, Ding CM, Song X, Ma ZY, Ren XL, Feng JF, Zhang HL, Chen GY, Han XH, Wu N, Yao C, Song Y, Zhang SC, Song W, Liu XQ, Zhao SJ, Lin YC, Ye XQ, Li K, Shu YQ, Ding LM, Tan FL, Sun Y. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol 2017; 28:2443-2450. [PMID: 28945850 DOI: 10.1093/annonc/mdx359] [Citation(s) in RCA: 181] [Impact Index Per Article: 25.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Icotinib has been previously shown to be non-inferior to gefitinib in non-selected advanced non-small-cell lung cancer patients when given as second- or further-line treatment. In this open-label, randomized, phase 3 CONVINCE trial, we assessed the efficacy and safety of first-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutation. PATIENTS AND METHODS Eligible participants were adults with stage IIIB/IV lung adenocarcinoma and exon 19/21 EGFR mutations. Participants were randomly allocated (1 : 1) to receive oral icotinib or 3-week cycle of cisplatin plus pemetrexed for up to four cycles; non-progressive patients after four cycles were maintained with pemetrexed until disease progression or intolerable toxicity. The primary end point was progression-free survival (PFS) assessed by independent response evaluation committee. Other end points included overall survival (OS) and safety. RESULTS Between January 2013 and August 2014, 296 patients were randomized, and 285 patients were treated (148 to icotinib, 137 to chemotherapy). Independent response evaluation committee-assessed PFS was significantly longer in the icotinib group (11.2 versus 7.9 months; hazard ratio, 0.61, 95% confidence interval 0.43-0.87; P = 0.006). No significant difference for OS was observed between treatments in the overall population or in EGFR-mutated subgroups (exon 19 Del/21 L858R). The most common grade 3 or 4 adverse events (AEs) in the icotinib group were rash (14.8%) and diarrhea (7.4%), compared with nausea (45.9%), vomiting (29.2%), and neutropenia (10.9%) in the chemotherapy group. AEs (79.1% versus 94.2%; P < 0.001) and treatment-related AEs (54.1% versus 90.5%; P < 0.001) were significantly fewer in the icotinib group than in the chemotherapy group. CONCLUSIONS First-line icotinib significantly improves PFS of advanced lung adenocarcinoma patients with EGFR mutation with a tolerable and manageable safety profile. Icotinib should be considered as a first-line treatment for this patient population.
Collapse
Affiliation(s)
- Y K Shi
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
| | - L Wang
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
| | - B H Han
- Department of Pulmonology, Shanghai Chest Hospital, Shanghai
| | - W Li
- Department of Oncology, The First Hospital Affiliated to Jilin University, Changchun
| | - P Yu
- Department of Lung Cancer Medical Oncology, Sichuan Cancer Hospital, Chengdu
| | - Y P Liu
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang
| | - C M Ding
- Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang
| | - X Song
- Department of Respiratory Medicine, Shanxi Provincial Tumor Hospital, Taiyuan
| | - Z Y Ma
- Department of Oncology, Henan Cancer Hospital, Zhengzhou
| | - X L Ren
- Department of Respiratory Medicine, Xijing Hospital, The Fourth Military Medical University, Xi'an
| | - J F Feng
- Department of Oncology, Jiangsu Cancer Hospital, Nanjing
| | - H L Zhang
- Department of Oncology, Tangdu Hospital, The Fourth Military Medical University, Xi'an
| | - G Y Chen
- Department of Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin
| | - X H Han
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
| | - N Wu
- Department of Imaging Diagnosis, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
| | - C Yao
- Department of Biostatistics, Peking University Clinical Research Institute, Beijing
| | - Y Song
- Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing
| | - S C Zhang
- Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing
| | - W Song
- Department of Radiology, Peking Union Medical College Hospital, Beijing
| | - X Q Liu
- Department of Pulmonary Oncology, The 307th Hospital of Chinese People's Liberation Army, Beijing
| | - S J Zhao
- Department of Imaging Diagnosis, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
| | - Y C Lin
- Department of Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou
| | - X Q Ye
- Department of Respiratory Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang
| | - K Li
- Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin
| | - Y Q Shu
- Department of Oncology, Jiangsu Provincial Hospital, Nanjing
| | - L M Ding
- Betta Pharmaceuticals Co., Ltd, Hangzhou, China
| | - F L Tan
- Betta Pharmaceuticals Co., Ltd, Hangzhou, China
| | - Y Sun
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
| |
Collapse
|
27
|
Wang SY, Chen SC, Lin YC, Kuo YC, Chen JY, Kao CM. Acidification and sulfide formation control during reductive dechlorination of 1,2-dichloroethane in groundwater: Effectiveness and mechanistic study. Chemosphere 2016; 160:216-229. [PMID: 27376861 DOI: 10.1016/j.chemosphere.2016.06.066] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2015] [Revised: 03/21/2016] [Accepted: 06/17/2016] [Indexed: 06/06/2023]
Abstract
To enhance the reductive dechlorination of 1,2-dichloroethane (DCA) in groundwater, substrate injection may be required. However, substrate biodegradation causes groundwater acidification and sulfide production, which inhibits the bacteria responsible for DCA dechlorination and results in an odor problem. In the microcosm study, the effectiveness of the addition of ferrous sulfate (FS), desulfurization slag (DS), and nanoscale zero-valent iron (nZVI) on acidification and sulfide control was studied during reductive dechlorination of DCA, and the emulsified substrate (ES) was used as the substrate. Up to 94% of the sulfide was removed with FS and DS addition (0.25 wt%) (initial DCA concentration = 13.5 mg/L). FS and DS amendments resulted in the formation of a metal sulfide, which reduced the hydrogen sulfide concentration as well as the subsequent odor problem. Approximately 96% of the DCA was degraded under reductive dechlorination with nZVI or DS addition using ES as the substrate. In microcosms with nZVI or DS addition, the sulfide concentration was reduced to less than 15 μg/L. Acidification can be controlled via hydroxide ions production after nZVI oxidation and reaction of free CaO (released from DS) with water, which enhanced DCA dechlorination. The quantitative polymerase chain reaction results confirmed that the microcosms with nZVI added had the highest Dehalococcoides population (up to 2.5 × 10(8) gene copies/g soil) due to effective acidification control. The α-elimination mechanism was the main abiotic process, and reductive dechlorination dominated by Dehalococcides was the biotic mechanism that resulted in DCA removal. More than 22 bacterial species were detected, and dechlorinating bacteria existed in soils under alkaline and acidic conditions.
Collapse
Affiliation(s)
- S Y Wang
- Institute of Environmental Engineering, National Sun Yat-Sen University, Kaohsiung, Taiwan
| | - S C Chen
- Department of Life Sciences, National Central University, Chung-Li, Taiwan
| | - Y C Lin
- Institute of Environmental Engineering, National Sun Yat-Sen University, Kaohsiung, Taiwan
| | - Y C Kuo
- Formosa Petrochemical Co., Kaohsiung, Taiwan
| | - J Y Chen
- Formosa Petrochemical Co., Kaohsiung, Taiwan
| | - C M Kao
- Institute of Environmental Engineering, National Sun Yat-Sen University, Kaohsiung, Taiwan
| |
Collapse
|
28
|
Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW, Xu RH. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann Oncol 2016; 27:1074-1081. [PMID: 26940686 DOI: 10.1093/annonc/mdw101] [Citation(s) in RCA: 61] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Accepted: 02/17/2016] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND The optimal strategy of maintenance therapy for patients with mCRC is controversial. This study was to evaluate the efficacy and safety of maintenance therapy with capecitabine versus observation following inductive chemotherapy in patients with metastatic colorectal cancer. PATIENTS AND METHODS In this randomized, open-label, multicenter, phase III trial, patients who received 18-24 weeks of induction chemotherapy with XELOX or FOLFOX and achieved disease control were randomly assigned centrally (1:1) to receive maintenance therapy of capecitabine or only observation until disease progression. The primary end point was progression-free survival (PFS) from randomization; the secondary end points included overall survival (OS), PFS from induction treatment (PFS2) and safety. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT02027363. RESULTS Between 30 July 2010 and 15 September 2013, 274 patients were enrolled in the study from 11 sites in China and randomly assigned to maintenance group (n = 136) or observation group (n = 138). Clinicopathological characteristics were balanced in two groups. The median follow-up time from randomization was 29.0 months [interquartile range (IQR) 21-36 months]. The primary end point of PFS was statistically significantly longer in capecitabine maintenance group than in observation group {6.43 [95% confidence interval (CI) 5.26-7.71] versus 3.43 (2.83-4.16) months, HR 0.54 (0.42-0.70), P < 0.001}. The median OS of capecitabine maintenance group was longer than that of observation group, but not statistically significant [25.63 (22.46-27.80) versus 23.30 (19.68-26.92) months; HR 0.85 (0.64-1.11), P = 0.2247]. Similar safety profiles were observed in both arms. The most common grade 3 or 4 toxicities in capecitabine maintenance group versus observation group were neutropenia, hand-foot syndrome, and mucositis. CONCLUSIONS Maintenance therapy with a single agent of capecitabine can be considered an appropriate option following the induction of XELOX or FOLFOX in mCRC patients with acceptable toxicities. CLINICAL TRIALS NUMBER NCT02027363.
Collapse
Affiliation(s)
- H Y Luo
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou
| | - Y H Li
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou
| | - W Wang
- Department of Medical Oncology, The First People's Hospital of Foshan, Guangzhou
| | - Z Q Wang
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou
| | - X Yuan
- Department of Medical Oncology, Huizhou Central Hospital, Huizhou
| | - D Ma
- Department of Medical Oncology, Guangdong General Hospital, Guangzhou
| | - F H Wang
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou
| | - D S Zhang
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou
| | - D R Lin
- Department of Medical Oncology, Jiangmen Central Hospital, Jiangmen
| | - Y C Lin
- Department of Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou
| | - J Jia
- Department of Medical Oncology, Dongguan People's Hospital, Dongguan
| | - X H Hu
- Department of Medical Oncology, Tumor Hospital of Guangxi Medical University, Nanning
| | - J W Peng
- Department of Medical Oncology, Zhongshan People's Hospital, Zhongshan, China
| | - R H Xu
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou.
| |
Collapse
|
29
|
Hsiao J, Yuan TY, Tsai MS, Lu CY, Lin YC, Lee ML, Lin SW, Chang FC, Liu Pimentel H, Olive C, Coito C, Shen G, Young M, Thorne T, Lawrence M, Magistri M, Faghihi MA, Khorkova O, Wahlestedt C. Upregulation of Haploinsufficient Gene Expression in the Brain by Targeting a Long Non-coding RNA Improves Seizure Phenotype in a Model of Dravet Syndrome. EBioMedicine 2016; 9:257-277. [PMID: 27333023 PMCID: PMC4972487 DOI: 10.1016/j.ebiom.2016.05.011] [Citation(s) in RCA: 98] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2016] [Revised: 05/02/2016] [Accepted: 05/09/2016] [Indexed: 02/07/2023] Open
Abstract
Dravet syndrome is a devastating genetic brain disorder caused by heterozygous loss-of-function mutation in the voltage-gated sodium channel gene SCN1A. There are currently no treatments, but the upregulation of SCN1A healthy allele represents an appealing therapeutic strategy. In this study we identified a novel, evolutionary conserved mechanism controlling the expression of SCN1A that is mediated by an antisense non-coding RNA (SCN1ANAT). Using oligonucleotide-based compounds (AntagoNATs) targeting SCN1ANAT we were able to induce specific upregulation of SCN1A both in vitro and in vivo, in the brain of Dravet knock-in mouse model and a non-human primate. AntagoNAT-mediated upregulation of Scn1a in postnatal Dravet mice led to significant improvements in seizure phenotype and excitability of hippocampal interneurons. These results further elucidate the pathophysiology of Dravet syndrome and outline a possible new approach for the treatment of this and other genetic disorders with similar etiology.
Collapse
Affiliation(s)
- J Hsiao
- OPKO Health Inc., 10320 USA Today Way, Miramar, FL 33025, USA
| | - T Y Yuan
- OPKO Health Inc., 10320 USA Today Way, Miramar, FL 33025, USA
| | - M S Tsai
- Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University Hospital, College of Medicine, National Taiwan University, No. 1, Sec. 1, Jen-Ai Rd., Taipei 100, Taiwan
| | - C Y Lu
- Department of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei 106, Taiwan
| | - Y C Lin
- OPKO Health Inc., 10320 USA Today Way, Miramar, FL 33025, USA
| | - M L Lee
- Dep. Clinical Laboratory Science and Medical Biotechnology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan
| | - S W Lin
- Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University Hospital, College of Medicine, National Taiwan University, No. 1, Sec. 1, Jen-Ai Rd., Taipei 100, Taiwan; Department of Laboratory Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, No. 7, Chung-Shan S. Rd., Taipei 100, Taiwan; Center for Genomic Medicine, National Taiwan University, No. 7, Chung-Shan S. Rd., Taipei 100, Taiwan
| | - F C Chang
- Department of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei 106, Taiwan; Graduate Institute of Brain and Mind Sciences, College of Medicine, National Taiwan University, No. 1, Sec. 1, Jen-Ai Rd., Taipei 100, Taiwan; Graduate Institute of Acupuncture Science, College of Chinese Medicine, China Medical University, Taichung, Taiwan
| | - H Liu Pimentel
- OPKO Health Inc., 10320 USA Today Way, Miramar, FL 33025, USA
| | - C Olive
- OPKO Health Inc., 10320 USA Today Way, Miramar, FL 33025, USA
| | - C Coito
- OPKO Health Inc., 10320 USA Today Way, Miramar, FL 33025, USA
| | - G Shen
- OPKO Health Inc., 10320 USA Today Way, Miramar, FL 33025, USA
| | - M Young
- OPKO Health Inc., 10320 USA Today Way, Miramar, FL 33025, USA
| | - T Thorne
- OPKO Health Inc., 10320 USA Today Way, Miramar, FL 33025, USA
| | - M Lawrence
- RxGen, 100 Deepwood Drive, Hamden, CT 06517, USA
| | - M Magistri
- Center for Therapeutic Innovation and the Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, 1501 NW 10th Avenue, Miami 33136, FL, USA
| | - M A Faghihi
- Center for Therapeutic Innovation and the Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, 1501 NW 10th Avenue, Miami 33136, FL, USA
| | - O Khorkova
- OPKO Health Inc., 10320 USA Today Way, Miramar, FL 33025, USA
| | - C Wahlestedt
- Center for Therapeutic Innovation and the Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, 1501 NW 10th Avenue, Miami 33136, FL, USA.
| |
Collapse
|
30
|
Lin YC, Hu WY. P-73 Develop a culturally oriented advance care planning intervention model for community older adults in taiwan – a study protocol. BMJ Support Palliat Care 2015. [DOI: 10.1136/bmjspcare-2015-000978.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
31
|
Pi TW, Lin YH, Fanchiang YT, Chiang TH, Wei CH, Lin YC, Wertheim GK, Kwo J, Hong M. In-situ atomic layer deposition of tri-methylaluminum and water on pristine single-crystal (In)GaAs surfaces: electronic and electric structures. Nanotechnology 2015; 26:164001. [PMID: 25824203 DOI: 10.1088/0957-4484/26/16/164001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The electronic structure of single-crystal (In)GaAs deposited with tri-methylaluminum (TMA) and water via atomic layer deposition (ALD) is presented with high-resolution synchrotron radiation core-level photoemission and capacitance-voltage (CV) characteristics. The interaction of the precursor atoms with (In)GaAs is confined at the topmost surface layer. The Ga-vacant site on the GaAs(111)A-2 × 2 surface is filled with Al, thereby effectively passivating the As dangling bonds. The As-As dimers on the GaAs(001)-2 × 4 surface are entirely passivated by one cycle of TMA and water. The presumed layerwise deposition fails to happen in GaAs(001)-4 × 6. In In0.20Ga0.80As(001)-2 × 4, the edge row As atoms are partially bonded with the Al, and one released methyl then bonds with the In. It is suggested that the unpassivated surface and subsurface atoms cause large frequency dispersions in CV characteristics under the gate bias. We also found that the (In)GaAs surface is immune to water in ALD. However, the momentary exposure of it to air (less than one minute) introduces significant signals of native oxides. This indicates the necessity of in situ works of high κ/(In)GaAs-related experiments in order to know the precise interfacial atomic bonding and thus know the electronic characteristics. The electric CV measurements of the ALD-Al2O3 on these (In)GaAs surfaces are correlated with their electronic properties.
Collapse
Affiliation(s)
- T W Pi
- National Synchrotron Radiation Research Center, Hsinchu 30076, Taiwan
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Dalal DS, Lin YC, Brennan DM, Borkar N, Korman N, Husni ME. Quantifying harmful effects of psoriatic diseases on quality of life: Cardio-metabolic outcomes in psoriatic arthritis study (COMPASS). Semin Arthritis Rheum 2015; 44:641-5. [PMID: 26058346 DOI: 10.1016/j.semarthrit.2015.01.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2014] [Revised: 01/02/2015] [Accepted: 01/16/2015] [Indexed: 10/24/2022]
Abstract
OBJECTIVE Up to 30% of patients with psoriasis suffer from concurrent psoriatic arthritis, and both the diseases have worse quality-of-life outcomes compared to the general population. There is limited literature comparing quality-of-life outcomes between these diseases. We seek to compare quality-of-life outcomes between both these groups. METHODS The current study is a cross-sectional analysis of a cohort of 252 patients with psoriatic diseases, who were recruited from 2 tertiary-care centers. A self-administered questionnaire was used to collect demographic and validated quality-of-life data using short form-12 (SF 12), health assessment questionnaire (HAQ), and dermatology life quality index (DLQI). Univariate and multivariate analyses were conducted to compare the quality-of-life outcomes. RESULTS We included 107 (42.5%) psoriatic arthritis and 145 (57.5%) psoriasis patients in the cohort. The groups had comparable gender distribution and co-morbid diseases prevalence, but arthritis patients were older and received biologics/DMARDs more frequently than psoriasis patients. The physical indices (identified by HAQ and SF 12 PCS) were worse for psoriatic arthritis, whereas the mental/psychometric indices (identified by DLQI and SF 12 MCS) were comparable between both the groups. CONCLUSIONS Despite aggressive therapy, physical quality of life was worse in psoriatic arthritis patients compared to psoriasis patients. The mental quality-of-life indices were comparable in both the groups and were still below the population norm. These results suggest need for screening for psoriatic arthritis in patients with psoriasis to reduce the burden of physical quality of life and screening for early signs of psychiatric illnesses in both these disease populations.
Collapse
Affiliation(s)
- Deepan S Dalal
- Rheumatology, Boston University Medical Center, Boston, MA
| | - Yih Chang Lin
- Division of Rheumatology, University of South Florida Morsani College of Medicine, Tampa, FL
| | - Danielle M Brennan
- Department of Rheumatology, Orthopedic and Rheumatologic Institute, Cleveland Clinic Foundation, Cleveland, OH
| | - Neil Borkar
- Baylor University Medical Center, Dallas, TX
| | - Neil Korman
- Department of Dermatology, University Hospitals - Case Medical Center, Cleveland, OH
| | - M Elaine Husni
- Department of Rheumatology, Orthopedic and Rheumatologic Institute, Cleveland Clinic Foundation, Cleveland, OH.
| |
Collapse
|
33
|
Lin YC, Su KW, Huang KF, Chen YF. Pattern formation of second harmonic conical waves in a nonlinear medium with extended defect structure. Opt Express 2014; 22:27859-27868. [PMID: 25402028 DOI: 10.1364/oe.22.027859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
We experimentally demonstrate the propagation of the conical second harmonic fields generated from a nonlinear crystal with extended defects to investigate their pattern formation. The generated second harmonic waves are found to be the interference of multiple Bessel-like beams that originate from distinct longitudinal layers inside the crystal. To reconstruct the experimental results, we model the individual Bessel-like beam to be the superposition of an ensemble of identical decentered Gaussian waves with random phases. We present that the randomness of the phases leads the Bessel-like beams to show wave profiles with different extent of localization. Moreover, we use the coherent superposition of the developed wave functions with a phase factor to manifest the interference of multiple Bessel-like beams. The relative phases among the Bessel-like beams are shown to be closely related to the near and far-field patterns. With the experimental observations and the theoretical model, the relative phases are decided to successfully reconstruct the propagation characteristics of the multiple Bessel-like beams.
Collapse
|
34
|
An FP, Balantekin AB, Band HR, Beriguete W, Bishai M, Blyth S, Butorov I, Cao GF, Cao J, Chan YL, Chang JF, Chang LC, Chang Y, Chasman C, Chen H, Chen QY, Chen SM, Chen X, Chen X, Chen YX, Chen Y, Cheng YP, Cherwinka JJ, Chu MC, Cummings JP, de Arcos J, Deng ZY, Ding YY, Diwan MV, Draeger E, Du XF, Dwyer DA, Edwards WR, Ely SR, Fu JY, Ge LQ, Gill R, Gonchar M, Gong GH, Gong H, Grassi M, Gu WQ, Guan MY, Guo XH, Hackenburg RW, Han GH, Hans S, He M, Heeger KM, Heng YK, Hinrichs P, Hor YK, Hsiung YB, Hu BZ, Hu LM, Hu LJ, Hu T, Hu W, Huang EC, Huang H, Huang XT, Huber P, Hussain G, Isvan Z, Jaffe DE, Jaffke P, Jen KL, Jetter S, Ji XP, Ji XL, Jiang HJ, Jiao JB, Johnson RA, Kang L, Kettell SH, Kramer M, Kwan KK, Kwok MW, Kwok T, Lai WC, Lau K, Lebanowski L, Lee J, Lei RT, Leitner R, Leung A, Leung JKC, Lewis CA, Li DJ, Li F, Li GS, Li QJ, Li WD, Li XN, Li XQ, Li YF, Li ZB, Liang H, Lin CJ, Lin GL, Lin PY, Lin SK, Lin YC, Ling JJ, Link JM, Littenberg L, Littlejohn BR, Liu DW, Liu H, Liu JL, Liu JC, Liu SS, Liu YB, Lu C, Lu HQ, Luk KB, Ma QM, Ma XY, Ma XB, Ma YQ, McDonald KT, McFarlane MC, McKeown RD, Meng Y, Mitchell I, Monari Kebwaro J, Nakajima Y, Napolitano J, Naumov D, Naumova E, Nemchenok I, Ngai HY, Ning Z, Ochoa-Ricoux JP, Olshevski A, Patton S, Pec V, Peng JC, Piilonen LE, Pinsky L, Pun CSJ, Qi FZ, Qi M, Qian X, Raper N, Ren B, Ren J, Rosero R, Roskovec B, Ruan XC, Shao BB, Steiner H, Sun GX, Sun JL, Tam YH, Tang X, Themann H, Tsang KV, Tsang RHM, Tull CE, Tung YC, Viren B, Vorobel V, Wang CH, Wang LS, Wang LY, Wang M, Wang NY, Wang RG, Wang W, Wang WW, Wang X, Wang YF, Wang Z, Wang Z, Wang ZM, Webber DM, Wei HY, Wei YD, Wen LJ, Whisnant K, White CG, Whitehead L, Wise T, Wong HLH, Wong SCF, Worcester E, Wu Q, Xia DM, Xia JK, Xia X, Xing ZZ, Xu JY, Xu JL, Xu J, Xu Y, Xue T, Yan J, Yang CC, Yang L, Yang MS, Yang MT, Ye M, Yeh M, Yeh YS, Young BL, Yu GY, Yu JY, Yu ZY, Zang SL, Zeng B, Zhan L, Zhang C, Zhang FH, Zhang JW, Zhang QM, Zhang Q, Zhang SH, Zhang YC, Zhang YM, Zhang YH, Zhang YX, Zhang ZJ, Zhang ZY, Zhang ZP, Zhao J, Zhao QW, Zhao Y, Zhao YB, Zheng L, Zhong WL, Zhou L, Zhou ZY, Zhuang HL, Zou JH. Search for a light sterile neutrino at Daya Bay. Phys Rev Lett 2014; 113:141802. [PMID: 25325631 DOI: 10.1103/physrevlett.113.141802] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/28/2014] [Indexed: 06/04/2023]
Abstract
A search for light sterile neutrino mixing was performed with the first 217 days of data from the Daya Bay Reactor Antineutrino Experiment. The experiment's unique configuration of multiple baselines from six 2.9 GW(th) nuclear reactors to six antineutrino detectors deployed in two near (effective baselines 512 m and 561 m) and one far (1579 m) underground experimental halls makes it possible to test for oscillations to a fourth (sterile) neutrino in the 10(-3) eV(2)<|Δm(41)(2) |< 0.3 eV(2) range. The relative spectral distortion due to the disappearance of electron antineutrinos was found to be consistent with that of the three-flavor oscillation model. The derived limits on sin(2) 2θ(14) cover the 10(-3) eV(2) ≲ |Δm(41)(2)| ≲ 0.1 eV(2) region, which was largely unexplored.
Collapse
Affiliation(s)
- F P An
- Institute of Modern Physics, East China University of Science and Technology, Shanghai
| | | | - H R Band
- University of Wisconsin, Madison, Wisconsin, USA
| | - W Beriguete
- Brookhaven National Laboratory, Upton, New York, USA
| | - M Bishai
- Brookhaven National Laboratory, Upton, New York, USA
| | - S Blyth
- Department of Physics, National Taiwan University, Taipei
| | - I Butorov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - G F Cao
- Institute of High Energy Physics, Beijing
| | - J Cao
- Institute of High Energy Physics, Beijing
| | - Y L Chan
- Chinese University of Hong Kong, Hong Kong
| | - J F Chang
- Institute of High Energy Physics, Beijing
| | - L C Chang
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - Y Chang
- National United University, Miao-Li
| | - C Chasman
- Brookhaven National Laboratory, Upton, New York, USA
| | - H Chen
- Institute of High Energy Physics, Beijing
| | | | - S M Chen
- Department of Engineering Physics, Tsinghua University, Beijing
| | - X Chen
- Chinese University of Hong Kong, Hong Kong
| | - X Chen
- Institute of High Energy Physics, Beijing
| | - Y X Chen
- North China Electric Power University, Beijing
| | - Y Chen
- Shenzhen University, Shenzhen
| | - Y P Cheng
- Institute of High Energy Physics, Beijing
| | | | - M C Chu
- Chinese University of Hong Kong, Hong Kong
| | | | - J de Arcos
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois, USA
| | - Z Y Deng
- Institute of High Energy Physics, Beijing
| | - Y Y Ding
- Institute of High Energy Physics, Beijing
| | - M V Diwan
- Brookhaven National Laboratory, Upton, New York, USA
| | - E Draeger
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois, USA
| | - X F Du
- Institute of High Energy Physics, Beijing
| | - D A Dwyer
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
| | - W R Edwards
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
| | - S R Ely
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
| | - J Y Fu
- Institute of High Energy Physics, Beijing
| | - L Q Ge
- Chengdu University of Technology, Chengdu
| | - R Gill
- Brookhaven National Laboratory, Upton, New York, USA
| | - M Gonchar
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - G H Gong
- Department of Engineering Physics, Tsinghua University, Beijing
| | - H Gong
- Department of Engineering Physics, Tsinghua University, Beijing
| | - M Grassi
- Institute of High Energy Physics, Beijing
| | - W Q Gu
- Shanghai Jiao Tong University, Shanghai
| | - M Y Guan
- Institute of High Energy Physics, Beijing
| | - X H Guo
- Beijing Normal University, Beijing
| | | | - G H Han
- College of William and Mary, Williamsburg, Virginia, USA
| | - S Hans
- Brookhaven National Laboratory, Upton, New York, USA
| | - M He
- Institute of High Energy Physics, Beijing
| | - K M Heeger
- University of Wisconsin, Madison, Wisconsin, USA and Department of Physics, Yale University, New Haven, Connecticut, USA
| | - Y K Heng
- Institute of High Energy Physics, Beijing
| | - P Hinrichs
- University of Wisconsin, Madison, Wisconsin, USA
| | - Y K Hor
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia, USA
| | - Y B Hsiung
- Department of Physics, National Taiwan University, Taipei
| | - B Z Hu
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - L M Hu
- Brookhaven National Laboratory, Upton, New York, USA
| | - L J Hu
- Beijing Normal University, Beijing
| | - T Hu
- Institute of High Energy Physics, Beijing
| | - W Hu
- Institute of High Energy Physics, Beijing
| | - E C Huang
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
| | - H Huang
- China Institute of Atomic Energy, Beijing
| | | | - P Huber
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia, USA
| | - G Hussain
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Z Isvan
- Brookhaven National Laboratory, Upton, New York, USA
| | - D E Jaffe
- Brookhaven National Laboratory, Upton, New York, USA
| | - P Jaffke
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia, USA
| | - K L Jen
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - S Jetter
- Institute of High Energy Physics, Beijing
| | - X P Ji
- School of Physics, Nankai University, Tianjin
| | - X L Ji
- Institute of High Energy Physics, Beijing
| | - H J Jiang
- Chengdu University of Technology, Chengdu
| | | | - R A Johnson
- Department of Physics, University of Cincinnati, Cincinnati, Ohio, USA
| | - L Kang
- Dongguan University of Technology, Dongguan
| | - S H Kettell
- Brookhaven National Laboratory, Upton, New York, USA
| | - M Kramer
- Lawrence Berkeley National Laboratory, Berkeley, California, USA and Department of Physics, University of California, Berkeley, California, USA
| | - K K Kwan
- Chinese University of Hong Kong, Hong Kong
| | - M W Kwok
- Chinese University of Hong Kong, Hong Kong
| | - T Kwok
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - W C Lai
- Chengdu University of Technology, Chengdu
| | - K Lau
- Department of Physics, University of Houston, Houston, Texas, USA
| | - L Lebanowski
- Department of Engineering Physics, Tsinghua University, Beijing
| | - J Lee
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
| | - R T Lei
- Dongguan University of Technology, Dongguan
| | - R Leitner
- Charles University, Faculty of Mathematics and Physics, Prague
| | - A Leung
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - J K C Leung
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - C A Lewis
- University of Wisconsin, Madison, Wisconsin, USA
| | - D J Li
- University of Science and Technology of China, Hefei
| | - F Li
- Institute of High Energy Physics, Beijing and Chengdu University of Technology, Chengdu
| | - G S Li
- Shanghai Jiao Tong University, Shanghai
| | - Q J Li
- Institute of High Energy Physics, Beijing
| | - W D Li
- Institute of High Energy Physics, Beijing
| | - X N Li
- Institute of High Energy Physics, Beijing
| | - X Q Li
- School of Physics, Nankai University, Tianjin
| | - Y F Li
- Institute of High Energy Physics, Beijing
| | - Z B Li
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - H Liang
- University of Science and Technology of China, Hefei
| | - C J Lin
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
| | - G L Lin
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - P Y Lin
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - S K Lin
- Department of Physics, University of Houston, Houston, Texas, USA
| | - Y C Lin
- Chengdu University of Technology, Chengdu
| | - J J Ling
- Brookhaven National Laboratory, Upton, New York, USA and Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
| | - J M Link
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia, USA
| | - L Littenberg
- Brookhaven National Laboratory, Upton, New York, USA
| | - B R Littlejohn
- Department of Physics, University of Cincinnati, Cincinnati, Ohio, USA
| | - D W Liu
- Department of Physics, University of Houston, Houston, Texas, USA
| | - H Liu
- Department of Physics, University of Houston, Houston, Texas, USA
| | - J L Liu
- Shanghai Jiao Tong University, Shanghai
| | - J C Liu
- Institute of High Energy Physics, Beijing
| | - S S Liu
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - Y B Liu
- Institute of High Energy Physics, Beijing
| | - C Lu
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey, USA
| | - H Q Lu
- Institute of High Energy Physics, Beijing
| | - K B Luk
- Lawrence Berkeley National Laboratory, Berkeley, California, USA and Department of Physics, University of California, Berkeley, California, USA
| | - Q M Ma
- Institute of High Energy Physics, Beijing
| | - X Y Ma
- Institute of High Energy Physics, Beijing
| | - X B Ma
- North China Electric Power University, Beijing
| | - Y Q Ma
- Institute of High Energy Physics, Beijing
| | - K T McDonald
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey, USA
| | | | - R D McKeown
- College of William and Mary, Williamsburg, Virginia, USA and California Institute of Technology, Pasadena, California, USA
| | - Y Meng
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia, USA
| | - I Mitchell
- Department of Physics, University of Houston, Houston, Texas, USA
| | | | - Y Nakajima
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
| | - J Napolitano
- Department of Physics, College of Science and Technology, Temple University, Philadelphia, Pennsylvania, USA
| | - D Naumov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - E Naumova
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - I Nemchenok
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - H Y Ngai
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - Z Ning
- Institute of High Energy Physics, Beijing
| | - J P Ochoa-Ricoux
- Lawrence Berkeley National Laboratory, Berkeley, California, USA and Instituto de Física, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - A Olshevski
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - S Patton
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
| | - V Pec
- Charles University, Faculty of Mathematics and Physics, Prague
| | - J C Peng
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
| | - L E Piilonen
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia, USA
| | - L Pinsky
- Department of Physics, University of Houston, Houston, Texas, USA
| | - C S J Pun
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - F Z Qi
- Institute of High Energy Physics, Beijing
| | - M Qi
- Nanjing University, Nanjing
| | - X Qian
- Brookhaven National Laboratory, Upton, New York, USA
| | - N Raper
- Department of Physics, Applied Physics, and Astronomy, Rensselaer Polytechnic Institute, Troy, New York, USA
| | - B Ren
- Dongguan University of Technology, Dongguan
| | - J Ren
- China Institute of Atomic Energy, Beijing
| | - R Rosero
- Brookhaven National Laboratory, Upton, New York, USA
| | - B Roskovec
- Charles University, Faculty of Mathematics and Physics, Prague
| | - X C Ruan
- China Institute of Atomic Energy, Beijing
| | - B B Shao
- Department of Engineering Physics, Tsinghua University, Beijing
| | - H Steiner
- Lawrence Berkeley National Laboratory, Berkeley, California, USA and Department of Physics, University of California, Berkeley, California, USA
| | - G X Sun
- Institute of High Energy Physics, Beijing
| | - J L Sun
- China General Nuclear Power Group, Shenzhen
| | - Y H Tam
- Chinese University of Hong Kong, Hong Kong
| | - X Tang
- Institute of High Energy Physics, Beijing
| | - H Themann
- Brookhaven National Laboratory, Upton, New York, USA
| | - K V Tsang
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
| | - R H M Tsang
- California Institute of Technology, Pasadena, California, USA
| | - C E Tull
- Lawrence Berkeley National Laboratory, Berkeley, California, USA
| | - Y C Tung
- Department of Physics, National Taiwan University, Taipei
| | - B Viren
- Brookhaven National Laboratory, Upton, New York, USA
| | - V Vorobel
- Charles University, Faculty of Mathematics and Physics, Prague
| | - C H Wang
- National United University, Miao-Li
| | - L S Wang
- Institute of High Energy Physics, Beijing
| | - L Y Wang
- Institute of High Energy Physics, Beijing
| | - M Wang
- Shandong University, Jinan
| | - N Y Wang
- Beijing Normal University, Beijing
| | - R G Wang
- Institute of High Energy Physics, Beijing
| | - W Wang
- College of William and Mary, Williamsburg, Virginia, USA and Sun Yat-Sen (Zhongshan) University, Guangzhou
| | | | - X Wang
- College of Electronic Science and Engineering, National University of Defense Technology, Changsha
| | - Y F Wang
- Institute of High Energy Physics, Beijing
| | - Z Wang
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Z Wang
- Institute of High Energy Physics, Beijing
| | - Z M Wang
- Institute of High Energy Physics, Beijing
| | - D M Webber
- University of Wisconsin, Madison, Wisconsin, USA
| | - H Y Wei
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Y D Wei
- Dongguan University of Technology, Dongguan
| | - L J Wen
- Institute of High Energy Physics, Beijing
| | | | - C G White
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois, USA
| | - L Whitehead
- Department of Physics, University of Houston, Houston, Texas, USA
| | - T Wise
- University of Wisconsin, Madison, Wisconsin, USA
| | - H L H Wong
- Lawrence Berkeley National Laboratory, Berkeley, California, USA and Department of Physics, University of California, Berkeley, California, USA
| | - S C F Wong
- Chinese University of Hong Kong, Hong Kong
| | - E Worcester
- Brookhaven National Laboratory, Upton, New York, USA
| | - Q Wu
- Shandong University, Jinan
| | - D M Xia
- Institute of High Energy Physics, Beijing
| | - J K Xia
- Institute of High Energy Physics, Beijing
| | - X Xia
- Shandong University, Jinan
| | - Z Z Xing
- Institute of High Energy Physics, Beijing
| | - J Y Xu
- Chinese University of Hong Kong, Hong Kong
| | - J L Xu
- Institute of High Energy Physics, Beijing
| | - J Xu
- Beijing Normal University, Beijing
| | - Y Xu
- School of Physics, Nankai University, Tianjin
| | - T Xue
- Department of Engineering Physics, Tsinghua University, Beijing
| | - J Yan
- Xi'an Jiaotong University, Xi'an
| | - C C Yang
- Institute of High Energy Physics, Beijing
| | - L Yang
- Dongguan University of Technology, Dongguan
| | - M S Yang
- Institute of High Energy Physics, Beijing
| | | | - M Ye
- Institute of High Energy Physics, Beijing
| | - M Yeh
- Brookhaven National Laboratory, Upton, New York, USA
| | - Y S Yeh
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - B L Young
- Iowa State University, Ames, Iowa, USA
| | - G Y Yu
- Nanjing University, Nanjing
| | - J Y Yu
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Z Y Yu
- Institute of High Energy Physics, Beijing
| | | | - B Zeng
- Chengdu University of Technology, Chengdu
| | - L Zhan
- Institute of High Energy Physics, Beijing
| | - C Zhang
- Brookhaven National Laboratory, Upton, New York, USA
| | - F H Zhang
- Institute of High Energy Physics, Beijing
| | - J W Zhang
- Institute of High Energy Physics, Beijing
| | | | - Q Zhang
- Chengdu University of Technology, Chengdu
| | - S H Zhang
- Institute of High Energy Physics, Beijing
| | - Y C Zhang
- University of Science and Technology of China, Hefei
| | - Y M Zhang
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Y H Zhang
- Institute of High Energy Physics, Beijing
| | - Y X Zhang
- China General Nuclear Power Group, Shenzhen
| | - Z J Zhang
- Dongguan University of Technology, Dongguan
| | - Z Y Zhang
- Institute of High Energy Physics, Beijing
| | - Z P Zhang
- University of Science and Technology of China, Hefei
| | - J Zhao
- Institute of High Energy Physics, Beijing
| | - Q W Zhao
- Institute of High Energy Physics, Beijing
| | - Y Zhao
- North China Electric Power University, Beijing and College of William and Mary, Williamsburg, Virginia, USA
| | - Y B Zhao
- Institute of High Energy Physics, Beijing
| | - L Zheng
- University of Science and Technology of China, Hefei
| | - W L Zhong
- Institute of High Energy Physics, Beijing
| | - L Zhou
- Institute of High Energy Physics, Beijing
| | - Z Y Zhou
- China Institute of Atomic Energy, Beijing
| | - H L Zhuang
- Institute of High Energy Physics, Beijing
| | - J H Zou
- Institute of High Energy Physics, Beijing
| |
Collapse
|
35
|
|
36
|
Tanigawa S, Lee CH, Lin CS, Ku CC, Hasegawa H, Qin S, Kawahara A, Korenori Y, Miyamori K, Noguchi M, Lee LH, Lin YC, Lin CLS, Nakamura Y, Jin C, Yamaguchi N, Eckner R, Hou DX, Yokoyama KK. Erratum: Jun dimerization protein 2 is a critical component of the Nrf2/MafK complex regulating the response to ROS homeostasis. Cell Death Dis 2014. [PMCID: PMC4123110 DOI: 10.1038/cddis.2014.322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
37
|
An FP, Balantekin AB, Band HR, Beriguete W, Bishai M, Blyth S, Brown RL, Butorov I, Cao GF, Cao J, Carr R, Chan YL, Chang JF, Chang Y, Chasman C, Chen HS, Chen HY, Chen SJ, Chen SM, Chen XC, Chen XH, Chen Y, Chen YX, Cheng YP, Cherwinka JJ, Chu MC, Cummings JP, de Arcos J, Deng ZY, Ding YY, Diwan MV, Draeger E, Du XF, Dwyer DA, Edwards WR, Ely SR, Fu JY, Ge LQ, Gill R, Gonchar M, Gong GH, Gong H, Gornushkin YA, Gu WQ, Guan MY, Guo XH, Hackenburg RW, Hahn RL, Han GH, Hans S, He M, Heeger KM, Heng YK, Hinrichs P, Hor Y, Hsiung YB, Hu BZ, Hu LJ, Hu LM, Hu T, Hu W, Huang EC, Huang HX, Huang HZ, Huang XT, Huber P, Hussain G, Isvan Z, Jaffe DE, Jaffke P, Jetter S, Ji XL, Ji XP, Jiang HJ, Jiao JB, Johnson RA, Kang L, Kettell SH, Kramer M, Kwan KK, Kwok MW, Kwok T, Lai WC, Lai WH, Lau K, Lebanowski L, Lee J, Lei RT, Leitner R, Leung A, Leung JKC, Lewis CA, Li DJ, Li F, Li GS, Li QJ, Li WD, Li XN, Li XQ, Li YF, Li ZB, Liang H, Lin CJ, Lin GL, Lin SK, Lin YC, Ling JJ, Link JM, Littenberg L, Littlejohn BR, Liu DW, Liu H, Liu JC, Liu JL, Liu SS, Liu YB, Lu C, Lu HQ, Luk KB, Ma QM, Ma XB, Ma XY, Ma YQ, McDonald KT, McFarlane MC, McKeown RD, Meng Y, Mitchell I, Nakajima Y, Napolitano J, Naumov D, Naumova E, Nemchenok I, Ngai HY, Ngai WK, Ning Z, Ochoa-Ricoux JP, Olshevski A, Patton S, Pec V, Peng JC, Piilonen LE, Pinsky L, Pun CSJ, Qi FZ, Qi M, Qian X, Raper N, Ren B, Ren J, Rosero R, Roskovec B, Ruan XC, Shao BB, Steiner H, Sun GX, Sun JL, Tam YH, Tanaka HK, Tang X, Themann H, Trentalange S, Tsai O, Tsang KV, Tsang RHM, Tull CE, Tung YC, Viren B, Vorobel V, Wang CH, Wang LS, Wang LY, Wang LZ, Wang M, Wang NY, Wang RG, Wang W, Wang WW, Wang X, Wang YF, Wang Z, Wang Z, Wang ZM, Webber DM, Wei H, Wei YD, Wen LJ, Whisnant K, White CG, Whitehead L, Wise T, Wong HLH, Wong SCF, Worcester E, Wu Q, Xia DM, Xia JK, Xia X, Xing ZZ, Xu J, Xu JL, Xu JY, Xu Y, Xue T, Yan J, Yang CG, Yang L, Yang MS, Ye M, Yeh M, Yeh YS, Young BL, Yu GY, Yu JY, Yu ZY, Zang SL, Zhan L, Zhang C, Zhang FH, Zhang JW, Zhang QM, Zhang SH, Zhang YC, Zhang YH, Zhang YM, Zhang YX, Zhang ZJ, Zhang ZP, Zhang ZY, Zhao J, Zhao QW, Zhao YB, Zheng L, Zhong WL, Zhou L, Zhou ZY, Zhuang HL, Zou JH. Spectral measurement of electron antineutrino oscillation amplitude and frequency at Daya Bay. Phys Rev Lett 2014; 112:061801. [PMID: 24580686 DOI: 10.1103/physrevlett.112.061801] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/2013] [Indexed: 06/03/2023]
Abstract
A measurement of the energy dependence of antineutrino disappearance at the Daya Bay reactor neutrino experiment is reported. Electron antineutrinos (ν¯(e)) from six 2.9 GW(th) reactors were detected with six detectors deployed in two near (effective baselines 512 and 561 m) and one far (1579 m) underground experimental halls. Using 217 days of data, 41 589 (203 809 and 92 912) antineutrino candidates were detected in the far hall (near halls). An improved measurement of the oscillation amplitude sin(2)2θ(13)=0.090(-0.009)(+0.008) and the first direct measurement of the ν¯(e) mass-squared difference |Δm(ee)2|=(2.59(-0.20)(+0.19))×10(-3) eV2 is obtained using the observed ν¯(e) rates and energy spectra in a three-neutrino framework. This value of |Δm(ee)2| is consistent with |Δm(μμ)2| measured by muon neutrino disappearance, supporting the three-flavor oscillation model.
Collapse
Affiliation(s)
- F P An
- Institute of High Energy Physics, Beijing and East China University of Science and Technology, Shanghai
| | | | - H R Band
- University of Wisconsin, Madison, Wisconsin
| | - W Beriguete
- Brookhaven National Laboratory, Upton, New York
| | - M Bishai
- Brookhaven National Laboratory, Upton, New York
| | - S Blyth
- Department of Physics, National Taiwan University, Taipei
| | - R L Brown
- Brookhaven National Laboratory, Upton, New York
| | - I Butorov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - G F Cao
- Institute of High Energy Physics, Beijing
| | - J Cao
- Institute of High Energy Physics, Beijing
| | - R Carr
- California Institute of Technology, Pasadena, California
| | - Y L Chan
- Chinese University of Hong Kong, Hong Kong
| | - J F Chang
- Institute of High Energy Physics, Beijing
| | - Y Chang
- National United University, Miao-Li
| | - C Chasman
- Brookhaven National Laboratory, Upton, New York
| | - H S Chen
- Institute of High Energy Physics, Beijing
| | - H Y Chen
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | | | - S M Chen
- Department of Engineering Physics, Tsinghua University, Beijing
| | - X C Chen
- Chinese University of Hong Kong, Hong Kong
| | - X H Chen
- Institute of High Energy Physics, Beijing
| | - Y Chen
- Shenzhen Univeristy, Shenzhen
| | - Y X Chen
- North China Electric Power University, Beijing
| | - Y P Cheng
- Institute of High Energy Physics, Beijing
| | | | - M C Chu
- Chinese University of Hong Kong, Hong Kong
| | | | - J de Arcos
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois
| | - Z Y Deng
- Institute of High Energy Physics, Beijing
| | - Y Y Ding
- Institute of High Energy Physics, Beijing
| | - M V Diwan
- Brookhaven National Laboratory, Upton, New York
| | - E Draeger
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois
| | - X F Du
- Institute of High Energy Physics, Beijing
| | - D A Dwyer
- Lawrence Berkeley National Laboratory, Berkeley, California
| | - W R Edwards
- Lawrence Berkeley National Laboratory, Berkeley, California and Department of Physics, University of California, Berkeley, California
| | - S R Ely
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois
| | - J Y Fu
- Institute of High Energy Physics, Beijing
| | - L Q Ge
- Chengdu University of Technology, Chengdu
| | - R Gill
- Brookhaven National Laboratory, Upton, New York
| | - M Gonchar
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - G H Gong
- Department of Engineering Physics, Tsinghua University, Beijing
| | - H Gong
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Y A Gornushkin
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - W Q Gu
- Shanghai Jiao Tong University, Shanghai
| | - M Y Guan
- Institute of High Energy Physics, Beijing
| | - X H Guo
- Beijing Normal University, Beijing
| | | | - R L Hahn
- Brookhaven National Laboratory, Upton, New York
| | - G H Han
- College of William and Mary, Williamsburg, Virginia
| | - S Hans
- Brookhaven National Laboratory, Upton, New York
| | - M He
- Institute of High Energy Physics, Beijing
| | - K M Heeger
- Department of Physics, Yale University, New Haven, Connecticut
| | - Y K Heng
- Institute of High Energy Physics, Beijing
| | - P Hinrichs
- University of Wisconsin, Madison, Wisconsin
| | - Yk Hor
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia
| | - Y B Hsiung
- Department of Physics, National Taiwan University, Taipei
| | - B Z Hu
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - L J Hu
- Beijing Normal University, Beijing
| | - L M Hu
- Brookhaven National Laboratory, Upton, New York
| | - T Hu
- Institute of High Energy Physics, Beijing
| | - W Hu
- Institute of High Energy Physics, Beijing
| | - E C Huang
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois
| | - H X Huang
- China Institute of Atomic Energy, Beijing
| | - H Z Huang
- University of California, Los Angeles, California
| | | | - P Huber
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia
| | - G Hussain
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Z Isvan
- Brookhaven National Laboratory, Upton, New York
| | - D E Jaffe
- Brookhaven National Laboratory, Upton, New York
| | - P Jaffke
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia
| | - S Jetter
- Institute of High Energy Physics, Beijing
| | - X L Ji
- Institute of High Energy Physics, Beijing
| | - X P Ji
- School of Physics, Nankai University, Tianjin
| | - H J Jiang
- Chengdu University of Technology, Chengdu
| | | | - R A Johnson
- Department of Physics, University of Cincinnati, Cincinnati, Ohio
| | - L Kang
- Dongguan University of Technology, Dongguan
| | - S H Kettell
- Brookhaven National Laboratory, Upton, New York
| | - M Kramer
- Lawrence Berkeley National Laboratory, Berkeley, California and Department of Physics, University of California, Berkeley, California
| | - K K Kwan
- Chinese University of Hong Kong, Hong Kong
| | - M W Kwok
- Chinese University of Hong Kong, Hong Kong
| | - T Kwok
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - W C Lai
- Chengdu University of Technology, Chengdu
| | - W H Lai
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - K Lau
- Department of Physics, University of Houston, Houston, Texas
| | - L Lebanowski
- Department of Engineering Physics, Tsinghua University, Beijing
| | - J Lee
- Lawrence Berkeley National Laboratory, Berkeley, California
| | - R T Lei
- Dongguan University of Technology, Dongguan
| | - R Leitner
- Charles University, Faculty of Mathematics and Physics, Prague
| | - A Leung
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - J K C Leung
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - C A Lewis
- University of Wisconsin, Madison, Wisconsin
| | - D J Li
- University of Science and Technology of China, Hefei
| | - F Li
- Institute of High Energy Physics, Beijing
| | - G S Li
- Shanghai Jiao Tong University, Shanghai
| | - Q J Li
- Institute of High Energy Physics, Beijing
| | - W D Li
- Institute of High Energy Physics, Beijing
| | - X N Li
- Institute of High Energy Physics, Beijing
| | - X Q Li
- School of Physics, Nankai University, Tianjin
| | - Y F Li
- Institute of High Energy Physics, Beijing
| | - Z B Li
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - H Liang
- University of Science and Technology of China, Hefei
| | - C J Lin
- Lawrence Berkeley National Laboratory, Berkeley, California
| | - G L Lin
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - S K Lin
- Department of Physics, University of Houston, Houston, Texas
| | - Y C Lin
- Chengdu University of Technology, Chengdu
| | - J J Ling
- Brookhaven National Laboratory, Upton, New York
| | - J M Link
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia
| | | | - B R Littlejohn
- Department of Physics, University of Cincinnati, Cincinnati, Ohio
| | - D W Liu
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois and Department of Physics, University of Houston, Houston, Texas
| | - H Liu
- Department of Physics, University of Houston, Houston, Texas
| | - J C Liu
- Institute of High Energy Physics, Beijing
| | - J L Liu
- Shanghai Jiao Tong University, Shanghai
| | - S S Liu
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - Y B Liu
- Institute of High Energy Physics, Beijing
| | - C Lu
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey
| | - H Q Lu
- Institute of High Energy Physics, Beijing
| | - K B Luk
- Lawrence Berkeley National Laboratory, Berkeley, California and Department of Physics, University of California, Berkeley, California
| | - Q M Ma
- Institute of High Energy Physics, Beijing
| | - X B Ma
- North China Electric Power University, Beijing
| | - X Y Ma
- Institute of High Energy Physics, Beijing
| | - Y Q Ma
- Institute of High Energy Physics, Beijing
| | - K T McDonald
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey
| | | | - R D McKeown
- College of William and Mary, Williamsburg, Virginia
| | - Y Meng
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia
| | - I Mitchell
- Department of Physics, University of Houston, Houston, Texas
| | - Y Nakajima
- Lawrence Berkeley National Laboratory, Berkeley, California
| | - J Napolitano
- Department of Physics, Applied Physics, and Astronomy, Rensselaer Polytechnic Institute, Troy, New York
| | - D Naumov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - E Naumova
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - I Nemchenok
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - H Y Ngai
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - W K Ngai
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois
| | - Z Ning
- Institute of High Energy Physics, Beijing
| | | | - A Olshevski
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - S Patton
- Lawrence Berkeley National Laboratory, Berkeley, California
| | - V Pec
- Charles University, Faculty of Mathematics and Physics, Prague
| | - J C Peng
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois
| | - L E Piilonen
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia
| | - L Pinsky
- Department of Physics, University of Houston, Houston, Texas
| | - C S J Pun
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - F Z Qi
- Institute of High Energy Physics, Beijing
| | - M Qi
- Nanjing University, Nanjing
| | - X Qian
- Brookhaven National Laboratory, Upton, New York and California Institute of Technology, Pasadena, California
| | - N Raper
- Department of Physics, Applied Physics, and Astronomy, Rensselaer Polytechnic Institute, Troy, New York
| | - B Ren
- Dongguan University of Technology, Dongguan
| | - J Ren
- China Institute of Atomic Energy, Beijing
| | - R Rosero
- Brookhaven National Laboratory, Upton, New York
| | - B Roskovec
- Charles University, Faculty of Mathematics and Physics, Prague
| | - X C Ruan
- China Institute of Atomic Energy, Beijing
| | - B B Shao
- Department of Engineering Physics, Tsinghua University, Beijing
| | - H Steiner
- Lawrence Berkeley National Laboratory, Berkeley, California and Department of Physics, University of California, Berkeley, California
| | - G X Sun
- Institute of High Energy Physics, Beijing
| | - J L Sun
- China Guangdong Nuclear Power Group, Shenzhen
| | - Y H Tam
- Chinese University of Hong Kong, Hong Kong
| | - H K Tanaka
- Brookhaven National Laboratory, Upton, New York
| | - X Tang
- Institute of High Energy Physics, Beijing
| | - H Themann
- Brookhaven National Laboratory, Upton, New York
| | | | - O Tsai
- University of California, Los Angeles, California
| | - K V Tsang
- Lawrence Berkeley National Laboratory, Berkeley, California
| | - R H M Tsang
- California Institute of Technology, Pasadena, California
| | - C E Tull
- Lawrence Berkeley National Laboratory, Berkeley, California
| | - Y C Tung
- Department of Physics, National Taiwan University, Taipei
| | - B Viren
- Brookhaven National Laboratory, Upton, New York
| | - V Vorobel
- Charles University, Faculty of Mathematics and Physics, Prague
| | - C H Wang
- National United University, Miao-Li
| | - L S Wang
- Institute of High Energy Physics, Beijing
| | - L Y Wang
- Institute of High Energy Physics, Beijing
| | - L Z Wang
- North China Electric Power University, Beijing
| | - M Wang
- Shandong University, Jinan
| | - N Y Wang
- Beijing Normal University, Beijing
| | - R G Wang
- Institute of High Energy Physics, Beijing
| | - W Wang
- College of William and Mary, Williamsburg, Virginia
| | | | - X Wang
- College of Electronic Science and Engineering, National University of Defense Technology, Changsha
| | - Y F Wang
- Institute of High Energy Physics, Beijing
| | - Z Wang
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Z Wang
- Institute of High Energy Physics, Beijing
| | - Z M Wang
- Institute of High Energy Physics, Beijing
| | - D M Webber
- University of Wisconsin, Madison, Wisconsin
| | - H Wei
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Y D Wei
- Dongguan University of Technology, Dongguan
| | - L J Wen
- Institute of High Energy Physics, Beijing
| | | | - C G White
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois
| | - L Whitehead
- Department of Physics, University of Houston, Houston, Texas
| | - T Wise
- University of Wisconsin, Madison, Wisconsin
| | - H L H Wong
- Lawrence Berkeley National Laboratory, Berkeley, California and Department of Physics, University of California, Berkeley, California
| | - S C F Wong
- Chinese University of Hong Kong, Hong Kong
| | - E Worcester
- Brookhaven National Laboratory, Upton, New York
| | - Q Wu
- Shandong University, Jinan
| | - D M Xia
- Institute of High Energy Physics, Beijing
| | - J K Xia
- Institute of High Energy Physics, Beijing
| | - X Xia
- Shandong University, Jinan
| | - Z Z Xing
- Institute of High Energy Physics, Beijing
| | - J Xu
- Beijing Normal University, Beijing
| | - J L Xu
- Institute of High Energy Physics, Beijing
| | - J Y Xu
- Chinese University of Hong Kong, Hong Kong
| | - Y Xu
- School of Physics, Nankai University, Tianjin
| | - T Xue
- Department of Engineering Physics, Tsinghua University, Beijing
| | - J Yan
- Xi'an Jiaotong University, Xi'an
| | - C G Yang
- Institute of High Energy Physics, Beijing
| | - L Yang
- Dongguan University of Technology, Dongguan
| | - M S Yang
- Institute of High Energy Physics, Beijing
| | - M Ye
- Institute of High Energy Physics, Beijing
| | - M Yeh
- Brookhaven National Laboratory, Upton, New York
| | - Y S Yeh
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | | | - G Y Yu
- Nanjing University, Nanjing
| | - J Y Yu
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Z Y Yu
- Institute of High Energy Physics, Beijing
| | | | - L Zhan
- Institute of High Energy Physics, Beijing
| | - C Zhang
- Brookhaven National Laboratory, Upton, New York
| | - F H Zhang
- Institute of High Energy Physics, Beijing
| | - J W Zhang
- Institute of High Energy Physics, Beijing
| | | | - S H Zhang
- Institute of High Energy Physics, Beijing
| | - Y C Zhang
- University of Science and Technology of China, Hefei
| | - Y H Zhang
- Institute of High Energy Physics, Beijing
| | - Y M Zhang
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Y X Zhang
- China Guangdong Nuclear Power Group, Shenzhen
| | - Z J Zhang
- Dongguan University of Technology, Dongguan
| | - Z P Zhang
- University of Science and Technology of China, Hefei
| | - Z Y Zhang
- Institute of High Energy Physics, Beijing
| | - J Zhao
- Institute of High Energy Physics, Beijing
| | - Q W Zhao
- Institute of High Energy Physics, Beijing
| | - Y B Zhao
- Institute of High Energy Physics, Beijing
| | - L Zheng
- University of Science and Technology of China, Hefei
| | - W L Zhong
- Institute of High Energy Physics, Beijing
| | - L Zhou
- Institute of High Energy Physics, Beijing
| | - Z Y Zhou
- China Institute of Atomic Energy, Beijing
| | - H L Zhuang
- Institute of High Energy Physics, Beijing
| | - J H Zou
- Institute of High Energy Physics, Beijing
| |
Collapse
|
38
|
Lin YC, Dalal D, Churton S, Brennan DM, Korman NJ, Kim ESH, Husni ME. Relationship Between Metabolic Syndrome and Carotid Intima-Media Thickness: Cross-Sectional Comparison Between Psoriasis and Psoriatic Arthritis. Arthritis Care Res (Hoboken) 2013; 66:97-103. [DOI: 10.1002/acr.22144] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2013] [Accepted: 08/20/2013] [Indexed: 02/06/2023]
Affiliation(s)
| | | | - Sarah Churton
- University Hospitals Case Medical Center; Cleveland Ohio
| | | | - Neil J. Korman
- University Hospitals Case Medical Center; Cleveland Ohio
| | | | | |
Collapse
|
39
|
Chen W, Lv YT, Zhang HX, Ruan D, Wang S, Lin YC. Developmental specificity in skeletal muscle of late-term avian embryos and its potential manipulation. Poult Sci 2013; 92:2754-64. [PMID: 24046424 DOI: 10.3382/ps.2013-03099] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Unlike the mammalian fetus, development of the avian embryo is independent of the maternal uterus and is potentially vulnerable to physiological and environmental stresses close to hatch. In contrast to the fetus of late gestation in mammals, skeletal muscle in avian embryos during final incubation shows differential developmental characteristics: 1) muscle mobilization (also called atrophy) is selectively enhanced in the type II fibers (pectoral muscle) but not in the type I fibers (biceps femoris and semimembranosus muscle), involving activation of ubiquitin-mediated protein degradation and suppression of S6K1-mediated protein translation; 2) the proliferative activity of satellite cells is decreased in the atrophied muscle of late-term embryos but enhanced at the day of hatch, probably preparing for the postnatal growth. The mobilization of muscle may represent an adaptive response of avian embryos to external (environmental) or internal (physiological) changes, considering there are developmental transitions both in hormones and requirements for glycolytic substrates from middle-term to late-term incubation. Although the exact mechanism triggering muscle fiber atrophy is still unknown, nutritional and endocrine changes may be of importance. The atrophied muscle fiber recovers as soon as feed and water are available to the hatchling. In ovo feeding of late-term embryos has been applied to improve the nutritional status and therein enhances muscle development. Similarly, in ovo exposure to higher temperature or green light during the critical period of muscle development are also demonstrated to be potential strategies to promote pre- and posthatch muscle growth.
Collapse
Affiliation(s)
- W Chen
- Institute of Animal Science, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China
| | | | | | | | | | | |
Collapse
|
40
|
Lin YC, Dalal D, Brennan DM, Kim ESH, Husni ME, Churton S, Korman NJ. Reply: To PMID 23983044. Arthritis Care Res (Hoboken) 2013; 66:793-4. [PMID: 24151237 DOI: 10.1002/acr.22209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
41
|
Yang SK, Tan N, Yan XM, Chen F, Long W, Lin YC. Thorium(IV) removal from aqueous medium by citric acid treated mangrove endophytic fungus Fusarium sp. #ZZF51. Mar Pollut Bull 2013; 74:213-219. [PMID: 23871201 DOI: 10.1016/j.marpolbul.2013.06.055] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/13/2013] [Revised: 06/23/2013] [Accepted: 06/26/2013] [Indexed: 06/02/2023]
Abstract
Thorium(IV) biosorption is investigated by citric acid treated mangrove endophytic fungus Fussarium sp. #ZZF51 (CA-ZZF51) from South China Sea. The biosorption process was optimized at pH 4.5, equilibrium time 90 min, initial thorium(IV) concentration 50 mg L(-1) and adsorbent dose 0.6 g L(-1) with 90.87% of removal efficiency and 75.47 mg g(-1) of adsorption capacity, which is obviously greater than that (11.35 mg g(-1)) of the untreated fungus Fussarium sp. #ZZF51 for thorium(IV) biosorption under the condition of optimization. The experimental data are analyzed by using isotherm and kinetic models. Kinetic data follow the pseudo-second-order model and equilibrium data agree very well with the Langmuir model. In addition, FTIR analysis indicates that hydroxyl, amino, and carbonyl groups act as the important roles in the adsorption process.
Collapse
Affiliation(s)
- S K Yang
- School of Chemistry and Chemical Engineering, University of South China, Hengyang, Hunan 421001, China.
| | | | | | | | | | | |
Collapse
|
42
|
Castrejón I, Pincus T, Soubrier M, Lin YC, Rat AC, Combe B, Dougados M. GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate. Rheumatology (Oxford) 2013; 52:1890-7. [PMID: 23864169 PMCID: PMC3775294 DOI: 10.1093/rheumatology/ket230] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
Objective. To analyse seven RA Core Data Set measures and three indices for their capacity to distinguish treatment results in early RA in the GUEPARD treat-to-target clinical trial vs ESPOIR routine care. Methods.Post hoc analyses compared 65 GUEPARD and 130 matched control ESPOIR patients over 6 and 12 months for mean changes in measures, relative efficiencies and standardized response means (SRM). Three indices—28-joint disease activity score (DAS28), clinical disease activity index (CDAI) and routine assessment of patient index data (RAPID3)—were compared for mean changes and numbers of patients with high, moderate or low activity or remission using κ values. Results. Greater improvement was seen for GUEPARD vs ESPOIR, statistically significant for physician and patient global estimates and pain and health assessment questionnaire physical function (HAQ-FN), but not joint counts and laboratory tests. Relative efficiencies with tender joint count as the referent measure indicated that pain (2.57) and global estimates by patient (3.13) and physician (2.31) were most efficient in distinguishing GUEPARD from ESPOIR. Mean improvements in GUEPARD vs ESPOIR were −3.4 vs −2.6 for DAS28 (0–10) (24%), −29.8 vs −23.1 for CDAI (0–76) (23%) and −13.0 vs −7.8 for RAPID3 (0–30) (40%) (all P < 0.01); agreement was moderate between CDAI vs DAS28 (κ = 0.56) and vs RAPID3 (κ = 0.48), and fair between DAS28 vs RAPID3 (κ = 0.26). Conclusion. Patient and global measures indicate greater efficacy than joint counts or laboratory measures in detecting difference between GUEPARD treat-to-target and ESPOIR routine care. A RAPID3 of only patient measures may help guide treat-to-target in busy clinical settings.
Collapse
Affiliation(s)
- Isabel Castrejón
- Division of Rheumatology, NYU Hospital for Joint Diseases, 301 East 17th Street, Room 1608, New York, NY 10003, USA.
| | | | | | | | | | | | | |
Collapse
|
43
|
Tseng LM, Hsu NC, Chen SC, Lu YS, Lin CH, Chang DY, Li H, Lin YC, Chang HK, Chao TC, Ouyang F, Hou MF. Distant metastasis in triple-negative breast cancer. Neoplasma 2013; 60:290-4. [PMID: 23373998 DOI: 10.4149/neo_2013_038] [Citation(s) in RCA: 71] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Triple-negative breast cancer (TNBC) relapses more frequently than hormone receptor-positive subtypes and is often associated with poor outcomes. This retrospective study reviewed the pattern of distant metastasis with regard to survival in patients with TNBC. A total of 205 TNBC patients were analyzed. TNBC patients with lung metastases had the longest median post-metastatic OS (with 95% confidence interval) of 16.6 (10.3-22.9) months, followed by the bone, 16.3 (11.7-20.8) months, the liver, 8.9 (3.5-14.4) months, the pleura, 7.5 (2.8-12.3) months, and the brain, 4.3 (0.6-8.0) months. Kaplan-Meier plots indicated that TNBC patients with metastatic spread to brain, liver, and pleural had poorer post-metastatic OS rate than patients with lung metastases (p = 0.001, 0.004, and 0.029, respectively). Moreover, brain and liver metastases correlated significantly with poorer post-metastatic OS as compared to bone metastasis (p = 0.004 and 0.011, respectively). Route of first metastasis correlated significantly with survival of TNBC patients with brain metastases being the poorest survival indicator, followed by metastases to liver, pleura, bone, and lung.
Collapse
Affiliation(s)
- L M Tseng
- Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Lo YC, Chen WC, Huang WT, Lin YC, Liu MC, Kuo HW, Chuang JH, Yang JR, Liu MT, Wu HS, Yang CH, Chou JH, Chang FY. Surveillance of avian influenza A(H7N9) virus infection in humans and detection of the first imported human case in Taiwan, 3 April to 10 May 2013. Euro Surveill 2013. [DOI: 10.2807/ese.18.20.20479-en] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
On 3 April 2013, suspected and confirmed cases of influenza A(H7N9) virus infection became notifiable in the primary care sector in Taiwan, and detection of the virus became part of the surveillance of severe community-acquired pneumonia. On 24 April, the first imported case, reported through both surveillance systems, was confirmed in a man returning from China by sequencing from endotracheal aspirates after two negative throat swabs. Three of 139 contacts were ill and tested influenza A(H7N9)-negative.
Collapse
Affiliation(s)
- Y C Lo
- Centers for Disease Control, Taipei, Taiwan
| | - W C Chen
- Centers for Disease Control, Taipei, Taiwan
| | - W T Huang
- Centers for Disease Control, Taipei, Taiwan
| | - Y C Lin
- Centers for Disease Control, Taipei, Taiwan
| | - M C Liu
- Centers for Disease Control, Taipei, Taiwan
| | - H W Kuo
- Centers for Disease Control, Taipei, Taiwan
| | - J H Chuang
- Centers for Disease Control, Taipei, Taiwan
| | - J R Yang
- Centers for Disease Control, Taipei, Taiwan
| | - M T Liu
- Centers for Disease Control, Taipei, Taiwan
| | - H S Wu
- Centers for Disease Control, Taipei, Taiwan
| | - C H Yang
- Centers for Disease Control, Taipei, Taiwan
| | - J H Chou
- Centers for Disease Control, Taipei, Taiwan
| | - F Y Chang
- Centers for Disease Control, Taipei, Taiwan
| |
Collapse
|
45
|
Lo YC, Chen WC, Huang WT, Lin YC, Liu MC, Kuo HW, Chuang JH, Yang JR, Liu MT, Wu HS, Yang CH, Chou JH, Chang FY. Surveillance of avian influenza A(H7N9) virus infection in humans and detection of the first imported human case in Taiwan, 3 April to 10 May 2013. Euro Surveill 2013; 18:20479. [PMID: 23725865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023] Open
Abstract
On 3 April 2013, suspected and confirmed cases of influenza A(H7N9) virus infection became notifiable in the primary care sector in Taiwan, and detection of the virus became part of the surveillance of severe community-acquired pneumonia. On 24 April, the first imported case, reported through both surveillance systems, was confirmed in a man returning from China by sequencing from endotracheal aspirates after two negative throat swabs. Three of 139 contacts were ill and tested influenza A(H7N9)-negative.
Collapse
Affiliation(s)
- Y C Lo
- Centers for Disease Control, Taipei, Taiwan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Wang YY, Lin YC, Hung HC, Tien WY, Shieh TY. Polymorphisms in Kallikrein7 and 10 genes and oral cancer risks in Taiwan betel quid chewers and smokers. Oral Dis 2013; 19:824-32. [PMID: 23413953 DOI: 10.1111/odi.12072] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2012] [Revised: 11/02/2012] [Accepted: 01/08/2013] [Indexed: 01/25/2023]
Abstract
OBJECTIVES We investigated the association between mRNA levels, polymorphisms of Kallikrein7 (KLK7) and Kallikrein10 (KLK10), and the development of oral squamous cell carcinoma (OSCC). MATERIALS AND METHODS We recruited 217 OSCC patients and 138 healthy controls. All were men, betel quid chewers, cigarette smokers, and Minnan ethnicity. Genotyping was performed using a TaqMan probe genotyping assay. Gene expression levels were determined using real-time polymerase chain reactions (PCRs) for 20 pairs of cancerous and non-cancerous tissues. RESULTS Kallikrein10 rs3745535G>T polymorphisms were significantly associated with OSCC development [adjusted OR (AOR) = 1.62, 95% CI = 1.02-2.59], but KLK7 polymorphisms were not. The KLK7 rs10581213(wt/ins + ins/ins) genotypes were significantly associated with early-stage cancer (AOR = 0.34, 95% CI = 0.14-0.78), but KLK10 polymorphisms were not. Relative expression analysis indicated that an increase in KLK7 and KLK10 mRNA levels was found in cancerous tissues (2(-ΔΔCT) = 25.23 ± 8.85 and 10.89 ± 4.97, respectively). A significantly higher level of KLK7 was expressed in early-stage cancer with the rs10581213(wt/ins + ins/ins) genotypes, but there was no significant difference in the mRNA levels of KLK7 and KLK10 between early- and advanced-stage cancers. CONCLUSIONS This is the first correlation of OSCC with KLK10 rs3745535G>T polymorphisms. Early-stage OSCC and high KLK7 mRNA levels were correlated with the rs10581213(wt/ins + ins/ins) genotypes. More studies with large sample sizes are needed to verify our findings.
Collapse
Affiliation(s)
- Y Y Wang
- School of Dentistry, Kaohsiung Medical University, Kaohsiung, Taiwan
| | | | | | | | | |
Collapse
|
47
|
Lin YH, Liu YS, Lin YC, Wei YS, Liao KS, Lee KR, Lai JY, Chen HM, Jean YC, Liu CY. Decoupling free-carriers contributions from oxygen-vacancy and cation-substitution in extrinsic conducting oxides. J Appl Phys 2013; 113:33706. [PMID: 23405036 PMCID: PMC3562333 DOI: 10.1063/1.4776781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/07/2012] [Accepted: 01/02/2013] [Indexed: 06/01/2023]
Abstract
The intrinsic oxygen-vacancies and the extrinsic dopants are two major fundamental free-carrier sources for the extrinsic conducting oxides, such as Sn-doped In(2)O(3). Yet, the individual contributions of the above two free-carrier sources to the total carrier concentrations have never been unraveled. A carrier-concentration separation model is derived in this work, which can define the individual contributions to the total carrier concentration from the intrinsic oxygen-vacancies and the extrinsic dopants, separately. The individual contributions obtained from the present carrier-concentration separation model are verified by the two-state trapping model, photoluminescence, and positron annihilation lifetime (PAL) spectroscopy. In addition, the oxygen-vacancy formation energy of the Sn:In(2)O(3) thin film is determined to be 0.25 eV by PAL spectroscopy.
Collapse
|
48
|
Shao KT, Lai KC, Lin YC, Chen LS, Li HY, Hsu CH, Lee H, Hsu HW, Mai GS. Experience and Strategy of Biodiversity Data Integration in Taiwan. Data Sci J 2013. [DOI: 10.2481/dsj.wds-008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Akira A, Ohmura H, Uzumcu M, Araki T, Lin YC. Gossypol inhibits aromatase activity in cultured porcine granulosa cells. Theriogenology 2012; 41:1489-97. [PMID: 16727503 DOI: 10.1016/0093-691x(94)90200-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/1993] [Accepted: 03/08/1994] [Indexed: 11/25/2022]
Abstract
The present study investigated whether gossypol inhibited aromatase activity in cultured porcine granulosa cells. Aromatase activity was assayed by measuring (3)H-H(2)O released from [1beta-(3)H]-androstenedione. First, immature porcine granulosa cells were cultured with various doses of follicle stimulating hormone (FSH, 1 to 1000 ng/ml) for 1 to 5 d to determine optimal culture conditions for aromatase activity assay. Second, porcine granulosa cells were cultured with or without FSH in the presence or absence of gossypol. Gossypol, at 4 muM, significantly inhibited FSH-induced aromatase activity while showing no effect on basal aromatase activity. Gossypol did not inhibit cell proliferation during cell culture. These results suggest that gossypol inhibits aromatase activity by interfering with FSH induction of aromatase in cultured porcine granulosa cells.
Collapse
Affiliation(s)
- A Akira
- Laboratory of Reproductive Endocrinology Department of Veterinary Physiology and Pharmacology College of Veterinary Medicine The Ohio State University 1900 Coffey Road Columbus, OH 43210-1092 USA
| | | | | | | | | |
Collapse
|
50
|
Zhu C, Jiang ZY, Jiang SQ, Zhou GL, Lin YC, Chen F, Hong P. Maternal energy and protein affect subsequent growth performance, carcass yield, and meat color in Chinese Yellow broilers. Poult Sci 2012; 91:1869-78. [PMID: 22802180 DOI: 10.3382/ps.2011-02059] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
This experiment was carried out to investigate effects of maternal ME and CP levels on growth performance, carcass traits, and meat quality of broiler offspring. A total of 1,134 thirty-week-old Chinese Yellow broiler breeders was randomly assigned to 3 dietary ME levels (11.09, 11.51, and 11.92 MJ/kg) and 3 CP levels (15.5, 16.5, and 17.5%) in a 3×3 factorial arrangement. Each dietary treatment had 6 replicates with 21 hens per replicate. At 39 wk of age, 30 settable eggs per replicate were selected for hatching. All broiler offspring were fed the same diets. There were significant ME×CP interactions in egg CP and ether extract (EE) contents, BW at d 1, 22 to 42 d ADG, ADFI during 1 to 21 d and 43 to 63 d, shear force, plasma albumin, cholesterol, and triglycerides contents of broiler offspring. Dietary ME at 11.92 MJ/kg increased average egg weight, egg EE content, and broiler 1-d-old BW compared with 11.09 MJ/kg group at 16.5%, 15.5%, and 17.5% CP levels, respectively (P<0.05). Maternal 11.51 and 11.92 MJ/kg of ME increased 1 to 21-d ADFI, and 11.51 MJ/kg of ME decreased lightness (L*) value of broiler offspring compared with 11.09 MJ/kg group at 17.5 and 16.5% CP levels, respectively (P<0.05). Broiler breeder dietary CP at 17.5% decreased egg EE content, increased average egg weight, egg CP content, BW at d 1, and 1 to 21-d ADFI of broiler offspring compared with 15.5% CP group at 11.92 MJ/kg of ME level (P<0.05). Maternal dietary 15.5% CP increased dressing percentage and decreased yellowness (b*) value of broiler offspring compared with 16.5% and 17.5% CP groups at 11.51 MJ/kg of ME level, respectively (P<0.05). Collectively, the results indicate that maternal diets composed of 11.51 to 11.92 MJ/kg of ME and 17.5% CP at 39 wk of age increased growth performance during 1 to 21 d in Chinese Yellow broiler, whereas 11.51 MJ/kg of ME and 15.5% CP improved carcass dressing percentage and meat color of their offspring.
Collapse
Affiliation(s)
- C Zhu
- College of Animal Science, South China Agricultural University, Guangzhou 510642, China
| | | | | | | | | | | | | |
Collapse
|